PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

United States Patent and Trademark Office
(Box PCT)
Crystal Plaza 2
Washington, DC 20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 03 July 1998 (03.07.98)	
International application No. PCT/US97/20226	**Applicant's or agent's file reference** 97,707
International filing date (day/month/year) 12 November 1997 (12.11.97)	**Priority date** (day/month/year) 12 November 1996 (12.11.96)
Applicant MADISON, Edwin, L.	

1. The designated Office is hereby notified of its election made:

[X] in the demand filed with the International Preliminary Examining Authority on:

10 June 1998 (10.06.98)

[ ] in a notice effecting later election filed with the International Bureau on:

2. The election [X] was

[ ] was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO **34, chemin des Colombettes** **1211 Geneva 20, Switzerland**	Authorized officer Maria Victoria CORTIELLO
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C12N 9/72

A2

(11) International Publication Number: WO 98/21320

(43) International Publication Date: 22 May 1998 (22.05.98)

(21) International Application Number: PCT/US97/20226

(22) International Filing Date: 12 November 1997 (12.11.97)

(30) Priority Data:
60/030,655 12 November 1996 (12.11.96) US

(71) Applicant *(for all designated States except US)*: THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10550 North Torrey Pines Road, LaJolla, CA 92037 (US).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: MADISON, Edwin, L. [US/US]; 615 Stratford Court No. 3, Del Mar, CA 92014 (US).

(74) Agent: ZIMMERMAN, Roger; McDonnell Boehnen Hulbert & Berghoff, 300 South Wacker Drive, Chicago, IL 60606 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: TISSUE TYPE PLASMINOGEN ACTIVATOR (t–PA) VARIANTS: COMPOSITIONS AND METHODS OF USE

(57) Abstract

Variants of tissue plasminogen factor exhibit significantly enhanced fibrin stimulation, dramatically increased discrimination among fibrin co–factors, marked resistance to inhibition by PAI–1, and substantially increased zymogenicity, a combination of properties that enhance the therapeutic utility of the enzyme.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

CORRECTED VERSION* | CORRECTED VERSION**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 9/72 // 15/55 — A3

(11) International Publication Number: WO 98/21320

(43) International Publication Date: 22 May 1998 (22.05.98)

(21) International Application Number: PCT/US97/20226

(22) International Filing Date: 12 November 1997 (12.11.97)

(30) Priority Data:
60/030,655 12 November 1996 (12.11.96) US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application
US 60/030,655 (CIP)
Filed on 12 November 1996 (12.11.96)

(71) Applicant *(for all designated States except US)*: THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10550 North Torrey Pines Road, LaJolla, CA 92037 (US).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: MADISON, Edwin, L. [US/US]; 615 Stratford Court No. 3, Del Mar, CA 92014 (US).

(74) Agent: ZIMMERMAN, Roger; McDonnell Boehnen Hulbert & Berghoff, 300 South Wacker Drive, Chicago, IL 60606 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report:
9 July 1998 (09.07.98)

(54) Title: TISSUE TYPE PLASMINOGEN ACTIVATOR (t-PA) VARIANTS: COMPOSITIONS AND METHODS OF USE

(57) Abstract

Variants of tissue plasminogen factor exhibit significantly enhanced fibrin stimulation, dramatically increased discrimination among fibrin co-factors, marked resistance to inhibition by PAI-1, and substantially increased zymogenicity, a combination of properties that enhance the therapeutic utility of the enzyme.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 9/72 // 15/55 — A3

(11) International Publication Number: **WO 98/21320**

(43) International Publication Date: 22 May 1998 (22.05.98)

(21) International Application Number: PCT/US97/20226

(22) International Filing Date: 12 November 1997 (12.11.97)

(30) Priority Data:
60/030,655 12 November 1996 (12.11.96) US

(71) Applicant *(for all designated States except US)*: THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10550 North Torrey Pines Road, LaJolla, CA 92037 (US).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: MADISON, Edwin, L. [US/US]; 615 Stratford Court No. 3, Del Mar, CA 92014 (US).

(74) Agent: ZIMMERMAN, Roger; McDonnell Boehnen Hulbert & Berghoff, 300 South Wacker Drive, Chicago, IL 60606 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report:
9 July 1998 (09.07.98)

(54) Title: TISSUE TYPE PLASMINOGEN ACTIVATOR (t–PA) VARIANTS: COMPOSITIONS AND METHODS OF USE

(57) Abstract

Variants of tissue plasminogen factor exhibit significantly enhanced fibrin stimulation, dramatically increased discrimination among fibrin co–factors, marked resistance to inhibition by PAI–1, and substantially increased zymogenicity, a combination of properties that enhance the therapeutic utility of the enzyme.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. ...onal Application No
PCT/US 97/20226

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0199574 A		JP 7040940 B	10-05-95
		JP 62000024 A	06-01-87
		NO 175216 B	06-06-94
		PT 82429 B	03-03-88
		US 5736134 A	07-04-98
		US 5714372 A	03-02-98
		US 5073494 A	17-12-91
		US 5147643 A	15-09-92
		US 5219569 A	15-06-93

Form PCT/ISA/210 (patent family annex) (July 1992)

CORRECTED VERSION*

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C12N 9/72 // 15/55

A3

(11) International Publication Number: WO 98/21320

(43) International Publication Date: 22 May 1998 (22.05.98)

(21) International Application Number: PCT/US97/20226

(22) International Filing Date: 12 November 1997 (12.11.97)

(30) Priority Data:
60/030,655 12 November 1996 (12.11.96) US

(71) Applicant *(for all designated States except US)*: THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10550 North Torrey Pines Road, LaJolla, CA 92037 (US).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: MADISON, Edwin, L. [US/US]; 615 Stratford Court No. 3, Del Mar, CA 92014 (US).

(74) Agent: ZIMMERMAN, Roger; McDonnell Boehnen Hulbert & Berghoff, 300 South Wacker Drive, Chicago, IL 60606 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report:
9 July 1998 (09.07.98)

(54) Title: TISSUE TYPE PLASMINOGEN ACTIVATOR (t-PA) VARIANTS: COMPOSITIONS AND METHODS OF USE

(57) Abstract

Variants of tissue plasminogen factor exhibit significantly enhanced fibrin stimulation, dramatically increased discrimination among fibrin co-factors, marked resistance to inhibition by PAI-1, and substantially increased zymogenicity, a combination of properties that enhance the therapeutic utility of the enzyme.

*(Referred to in PCT Gazette No. 34/1998, Section II)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

TISSUE TYPE PLASMINOGEN ACTIVATOR (t-PA) VARIANTS: COMPOSITIONS AND METHODS OF USE

Reference to Related Application

This application claims the benefit of U.S. Provisional Application S.N. 60/030,655, filed November 12, 1996, which is incorporated by reference.

Governmental Rights

This invention was made with governmental support from the United States Government, National Institutes of Health, Grants HL52475 and HL31950; the United States Government has certain rights in the invention.

The invention comprises protein single chain variants of tissue type plasminogen activator, also referred to as t-PA as well as nucleic acids encoding such protein single chain variants of tissue type plasminogen activator. The t-PA protein variants have higher zymogenicity than the wild-type single chain t-PA form. Methods of making and using the t-PA variant compositions are also described.

Background

Tissue-type plasminogen activator (t-PA) is a serine protease that plays a critical role in the process of fibrinolysis, the dissolution of clots, by activating plasminogen to the protease plasmin. t-PA has been fully identified and characterized by underlying DNA sequence and deduced amino acid sequence. See Pennica et al., *Nature*, **301**: 214 (1983) and U.S. Pat. No. 4,853,330, issued Aug. 1, 1989, the teachings of both of which are incorporated by reference. The nucleotide sequence and deduced primary amino acid sequence of human t-PA is depicted in Fig. 1A, Fig. 1B and Fig. 1C.

The group of amino acid residues from –35 to –1 preceding the sequence of the mature t-PA is the "pro" sequence. The mature t-PA molecule (amino acid residues 1-527) contains five domains that have been defined with reference to homologous or otherwise similar structures identified in various other proteins such as trypsin, chymotrypsin, plasminogen, prothrombin, fibronectin, and epidermal growth factor (EGF). These domains have been

designated, starting at the N-terminus of the amino acid sequence of mature t-PA, as 1) the finger region (F) that has variously been defined as including amino acid residues 1 to about 44, 2) the growth factor region (G) that has been variously defined as stretching from about amino acid residues 45 to 91 (based upon its homology with EGF), 3) kringle one (K1) that has been defined as stretching from about amino acid residue 92 to about amino acid residue 173, 4) kringle two (K2) that has been defined as stretching from about amino acid residue 180 to about amino acid residue 261, and 5) the so-called serine protease domain (P) that generally has been defined as stretching from about amino acid residue 264 to the C-terminal end of the molecule at amino acid residue 527. These domains, which are situated generally adjacent to one another, or are separated by short "linker" regions, account for the entire amino acid sequence of from 1 to 527 amino acid residues of the mature form of t-PA.

Each domain has been described variously as contributing certain specific biologically significant properties. The finger domain has been characterized as containing a sequence of at least major importance for high binding affinity to fibrin. (This activity is thought important for the high specificity that t-PA displays with respect to clot lysis at the locus of a fibrin-rich thrombus.) The growth factor-like region likewise has been associated with cell surface binding activity. The kringle 2 region also has been strongly associated with fibrin binding and with the ability of fibrin to stimulate the activity of t-PA. The serine protease domain is responsible for the enzymatic cleavage of plasminogen to produce plasmin.

t-PA is unusual among proteases in the level of the enzymatic activity of its precursor. In general, proteases are synthesized as zymogens, inactive precursors that must either be proteolytically processed or bind to a specific co-factor to develop substantial catalytic activity. The increase in catalytic efficiency after zymogen activation, or zymogenicity, is dramatic in almost all cases, although varying widely among individual members of the chymotrypsin family. For example, strong zymogens, i.e., those having high zymogenicity, such as trypsinogen, chymotrypsinogen, or plasminogen are almost completely inactive, with measured zymogenicities of 10^4 to 10^6 (Robinson, N. C., Neurath, H., and Walsh, K. A. (1973) *Biochemistry* **12**, 420-426; Gertler, A., Walsh, K. A., and Neurath, H. (1974) *Biochemistry* **13**, 1302-1310). Other serine proteases exhibit intermediate zymogenicity. For example, the enzymatic activity of Factor XIIa is 4000-fold greater than that of its corresponding zymogen, Factor XII (Silverberg, M., and Kaplan, A. P. (1982) *Blood* **60**, 64), and the catalytic efficiency of urokinase is 250-fold greater than that of pro-urokinase (Lijnen, H. R., Van Hoef,

B., Nelles, L., and Collen, D. (1990) *J. Biol. Chem.* **265**, 5232-5236). By contrast, the catalytic activities of single and two chain t-PA vary by a factor of only 5-10.

The zymogenicity, expressed as the ratio of the activity of the mature cleaved two-chain enzyme to that of the single chain precursor form, is only 5-10 for wild-type t-PA, in contrast to other precursors of other proteases that have little or no catalytic activity. Thus, the single chain form of wild-type t-PA is not a true zymogen.

There have been many attempts to improve the usefulness of t-PA by genetic engineering. These efforts have been only partially successful. The state of the art has been reviewed by Krause, J., & Tanswell, P. *Arzneim.-Forsch.* **39**: 632-637 (1989) and in U.S. patent No. 5,616,486, the teachings of both of which are incorporated by reference.

Despite the profound advantages associated with natural t-PA as a clot-dissolving agent, it is not believed that the natural protein necessarily represents the optimal t-PA agent under all circumstances. Therefore, several variants have been proposed or devised to enhance specific properties of t-PA. Certain of those variants address disadvantages associated with the use of natural t-PA in situations where an agent with a longer half-life or slower clearance rate would be preferred, e.g., in the treatment of deep-vein thrombosis and following reperfusion of an infarct victim, or where a single-chain agent is preferred.

For example, removal of a substantial portion or all of the finger domain results in a molecule with substantially diminished fibrin binding characteristics, albeit in return there is a decrease in the overall rate of clearance of the resultant entity—See WO 89/00197 published Jan. 12, 1989.

Variants are described in EPO Pat. Publ. No. 199,574 that have amino acid substitutions at the proteolytic cleavage sites at positions 275, 276, and 277. These variants, characterized preferentially as t-PA variants having an amino acid other than arginine at position 275, are referred to as protease-resistant one-chain t-PA variants in that, unlike natural t-PA, which can exist in either a one-chain or two-chain form, they are resistant to protease cleavage at position 275 and are therefore not converted metabolically in vivo into a two-chain form. This form is thought to have certain advantages biologically and commercially, in that it is more stable while the fibrin binding and fibrin stimulation are increased relative to two-chain t-PA. Furthermore, plasminogen activators are described that comprise one domain capable of interacting with fibrin and the protease domain of urokinase, with one embodiment

being urokinase altered to make it less susceptible to forming two-chain urokinase. See WO 88/05081 published Jul. 14, 1988.

For further patent literature regarding modification of the protease cleavage site of t-PA, see, for example, EPO Pat.Nos. 241,209; EP 201,153 published Nov. 12, 1986; EP 233,013 published Aug. 19, 1987; EP 292,009 published Nov. 23, 1988; EP 293,936 published Dec. 7, 1988; and EP 293,934 published Dec. 7, 1988; and WO 88/10119.

Glycosylation mutants at positions 117–119, 184–186, and 448–450 exhibited higher specific activity as the mole percent carbohydrate was reduced. See EPO Pub. No. 227,462 published Jul. 1, 1987. This patent application additionally discloses using an assay of fibrin/fibrin degradation products and teaches that one may also modify the t-PA molecule at positions 272–280 or delete up to 25 amino acids from the C-terminus. Further, the t-PA mutants with Asn 119, Ala 186 and Asn 450, which have the N-glycosylation sites selectively removed by DNA modification but contain residual O-linked carbohydrate, were found to be about two-fold as potent as melanoma t-PA in an in vitro lysis assay. See EPO Publ. No. 225,286 published Jun. 10, 1987.

Replacement of the amino acid at position 449 of t-PA with any amino acid except arginine to modify the glycosylation site, as well as modification of Arg 275 or deletion of the - 3 to 91 region, is also taught. See WO 87/04722 published Aug. 13, 1987. An amino acid substitution at position 448 of t-PA is disclosed as desirable to remove glycosylation. See EPO Pub. No. 297,066 published Dec. 28, 1988. The combination of modifications at positions 448–450 and deletion of the N-terminal 1–82 amino acids is disclosed by WO 89/00191 published Jan. 12, 1989. Additionally, urokinase has been modified in the region of Asp 302 -Ser 303 -Thr 304 to prevent glycosylation. See EPO Pub. No. 299,706 published Jan. 18, 1989.

However, alteration of the glycosylation sites, and in particular that at amino acid 117, seems invariably to result in a molecule having affected solubility characteristics that may result additionally in an altered circulating half-life pattern and/or fibrin binding characteristics. See EPO Pat. Publ. No. 238,304, published Sep. 23, 1987.

When the growth factor domain of t-PA is deleted, the resultant variant is still active and binds to fibrin, as reported by A. J. van Zonneveld et al., *Thrombos. Haemostas.* **54 (1):** 4 (1985). Various deletions in the growth factor domain have also been reported in the patent literature. See EPO Publ. No. 241,209 (del-51–87), EPO Publ. No. 241,208 (del-51-87 and

del-51–173), PCT 87/04722 (deletion of all or part of the N-terminal 1 - 91), EPO Publ. No. 231,624 (all of growth factor domain deleted), and EPO Publ. No. 242,836 and Jap. Pat. Appl. Kokai No. 62 - 269688 (some or all of the growth factor domain deleted).

It has further been shown that t-PA can be modified both in the region of the first kringle domain and in the growth factor domain, resulting in increased circulatory half-life. See EPO Pat. Publ. No. 241,208 published Oct. 14, 1987. The region between amino acids 51 and 87, inclusive, can be deleted from t-PA to result in a variant having slower clearance from plasma. Browne et al., *J. Biol. Chem.*, **263:** 1599–1602 (1988). Also, t-PA can be modified, without adverse biological effects, in the region of amino acids 67 to 69 of the mature, native t-PA, by deletion of certain amino acid residues or replacement of one or more amino acids with different amino acids. See EPO Pat. Publ. No. 240,334 published Oct. 7, 1987.

A hybrid of t-PA/urokinase using the region of t-PA encompassing amino acids 273 - 527 is also disclosed. See EPO 290,118 published Nov. 9, 1988. Serpin-resistant mutants of human t-PA with alterations in the protease domain, including del296-302 t-PA, R304S t-PA, and R304E t-PA, are disclosed in Madison et al., *Nature*, **339:** 721–724 (1989). The above list is not an exhaustive review of the numerous variants of t-PA that have described.

As a result of the catalytic activity of precursor t-PA, despite effective clot lysis at targeted sites, nondesirable proteolysis occurs systemically resulting in the deleterious depletion of circulating fibrinogen, α2-anti-plasmin and plasminogen. What is needed are more zymogenic t-PA variant proteins that provide effective local clot lysis is achieved with diminished systemic proteolytic effects.

Summary of the Invention

The present invention provides single chain variant t-PA proteins having at least two substitutions of basic amino acid residues by neutral or acidic amino acid residues, compared to the wild-type human t-PA, as well as polynucleotides encoding such single chain variant t-PA proteins. The single chain variant t-PA proteins of the present invention have the R275 amino acid residue substituted by an amino acid residue chosen from the group consisting of glycine, serine, threonine, asparagine, tyrosine, glutamine, aspartic acid, and glutamic acid. Preferably the single chain variant t-PA proteins of the present invention have the R275 amino

acid residue substituted by an amino acid residue chosen from the group consisting of an aspartic acid residue and a glutamic acid residue, and most preferably by a glutamic acid residue.

The single chain variant t-PA proteins of the present invention have additionally at least one other basic amino acid residue in the serine protease region residue substituted by a non-basic amino acid such that the salt bridge interaction normally found in wildtype single chain t-PA between aspartate 477 and lysine 429 is disrupted. Preferably, basic amino acids are replaced with polar or acidic amino acids, and more preferably, amino acid residues chosen from the group consisting of glycine, serine, threonine, asparagine, tyrosine, glutamine, aspartic acid and glutamic acid.

The salt bridge interaction between aspartate 477 and lysine 429 can be disrupted by a substitution at position 477 or 429, or by an appropriate substitution at a position within the serine protease region that provides an alternative salt bridge interaction partner for at least one of aspartate 477 and lysine 429. In one preferred embodiment, the H417 amino acid residue is substituted by an amino acid residue chosen from the group consisting of glycine, serine, threonine, asparagine, tyrosine, glutamine, aspartic acid, and glutamic acid. More preferably the single chain variant t-PA proteins of the present invention have both the R275 amino acid residue and the H417 amino acid residue substituted by an amino acid residue chosen from the group consisting of an aspartic acid residue and a glutamic acid residue. Two exemplary preferred single chain variant t-PA proteins are the t-PA variants designated as R275E,H417E and R275E,H417D.

In another preferred embodiment, the K429 amino acid residue is substituted by an amino acid residue chosen from the group consisting of glycine, serine, threonine, asparagine, tyrosine, glutamine, aspartic acid, and glutamic acid. More preferably the single chain variant t-PA proteins of the present invention have both the R275 amino acid residue and the K429 amino acid residue substituted by an amino acid residue chosen from the group consisting of glycine, serine, threonine, asparagine, tyrosine, glutamine, aspartic acid, and glutamic acid. One preferred single chain variant t-PA protein is the t-PA variant designated as R275E,K429Y.

The single chain variant t-PA proteins of the present invention exhibit greater zymogenicity, expressed as the ratio of the activity of the mature cleaved two-chain enzyme to that of the single chain precursor form, than that of the wild type single chain t-PA protein.

The single chain variant t-PA proteins of the present invention have zymogenicity of at least 10, preferably about 50 to about 200.

The single chain variant t-PA proteins of the present invention exhibit a greater fibrin stimulation factor, expressed as the ratio of the catalytic efficiencies in the presence and absence of fibrin, compared to the wild type single chain t-PA protein. The single chain variant t-PA proteins of the present invention have a fibrin stimulation factor of at least 7,000, preferably about 20,000 to about 50,000.

The single chain variant t-PA proteins of the present invention exhibit a reduced inhibition by plasminogen activator inhibitor 1 (PAI-1) to the wild type single chain t-PA protein. The single chain variant t-PA proteins of the present invention are at least a factor of 5, preferably at least a factor of about 9, most preferably at least a factor of about 200 less inhibited by PAI-1 compared to the wild type single chain t-PA protein.

The single chain variant t-PA proteins of the present invention exhibit a greater fibrin selectivity factor, expressed as the ratio of the catalytic efficiencies in the presence fibrin to that in the presence of fibrinogen, compared to the wild type single chain t-PA protein. Preferred embodiments of the single chain variant t-PA proteins of the present invention have a fibrin selectivity factor of at least 10, preferably at least 50, more preferably at least 100.

Brief Description of the Drawings

In the drawings,

Figs. 1A, 1B and 1C show the nucleotide sequence and deduced amino acid sequence of the full-length human t-PA cDNA; and

Fig. 2 is a graphical representation of the results of standard chromogenic assays of plasminogen activation in the presence of buffer (open squares), DESAFIB (open diamonds), fibrinogen (open circles), cyanogen bromide fragments of fibrinogen (open triangles) or the stimulatory peptide P368 (hatched squares).

Detailed Description of the Preferred Embodiments

As used herein, "wild-type t-PA" refers to the t-PA protein naturally occurring in humans. While this human t-PA is exemplified by the amino acid sequence depicted in Figs. 1A, 1B and 1C, the term wild-type t-PA should be understood to encompass naturally occurring allelic variations.

t-PA Variant Compositions

The t-PA variant cDNAs and the corresponding expressed recombinant proteins of this invention are useful compounds that function in the serine protease-mediated control of fibrinolysis as described herein.

The t-PA variant cDNAs of the present invention contain at least one nucleotide substitution to generate a t-PA cDNA that encodes a noncleavable single chain t-PA variant, i.e., not cleavable by plasmin under normal conditions. The nucleotide substitution results in a substitution of a glutamic acid (E) for an arginine (R) at amino acid residue 275 (or position 15 using the chymotrypsin numbering system) in the t-PA precursor that is responsible for creating a noncleavable variant. Positions 15, 144, 156, and 194 of the chymotrypsin numbering system correspond to positions 275, 417, 429, and 477, respectively, in the t-PA numbering system as depicted in Fig. 1.

The variants, which are substitution mutants, are designated by the single letter code of the wild type human t-PA amino acid residue, the position of the residue relative to the amino terminus of the mature human t-PA as depicted in Fig. 1, followed by the single letter code of the amino acid residue substituted for the amino acid residue in mature human t-PA. The substitution of glutamic acid for arginine at position 275 is designated as R275E. Equivalent substitutions generating noncleavable single chain t-PA are known in the art (Higgins, D.L., et al., (1990) *Thrombosis Res.* 57: 527-539).

In addition to the R275E substitution, the variant cDNAs of the present invention further comprise at least one other nucleotide substitution at a separate site to create a t-PA variant having at least two amino acid substitutions. Preferred cDNA variants include at least one nucleotide substitution that results in an amino acid substitution of an amino acid residue chosen from the group consisting of glycine, serine, threonine, asparagine, tyrosine, glutamine, aspartic acid, and glutamic acid for a histidine at amino acid residue position 417. Preferred embodiments are designated R275E,H417D and R275E,H417E. A further cDNA variant comprises at least one nucleotide substitution resulting in the substitution of an amino acid residue chosen from the group consisting of glycine, serine, threonine, asparagine, tyrosine, glutamine, aspartic acid, and glutamic acid for the lysine (K) at amino acid residue position 429. One such preferred embodiment is designated R275E,K429Y.

The variant t-PA cDNAs of the present invention are useful for generating the recombinant expressed variant t-PAs described above. In a further embodiment, the variant t-PA cDNAs have therapeutic uses in gene therapy as described below.

The invention includes embodiments such as expression vectors or plasmids in which the cDNAs for encoding variant t-PAs are operably linked to provide for the expression of recombinant variant t-PAs for use in the methods as described below. One preferred embodiment is the expression of a variant t-PA protein by COS 1 cells comprising pSVT7 expression vector operably linked to a polynucleotide encoding the variant protein. Constitutive and inducible expression vectors are disclosed. In a further embodiment, transiently and stably transfected cells contain cDNA encoding variant t-PAs.

The resultant recombinant expressed t-PA variants described herein are characterized as having one or more of the following structural and functional properties: 1) The t-PA variant is in the form of a noncleavable single chain protein containing an R275E amino acid substitution or equivalents thereof that prevent cleavage by t-PA activating enzymes; 2) The t-PA variant exhibits increased resistance to inhibition by the serpin plasminogen activator inhibitor, type I (PAI-1); 3) The t-PA variants has diminished catalytic activity on substrates, such as plasminogen, in the absence of co-factors, such as fibrin; 4) The t-PA variants exhibit enhanced stimulation by fibrin; 5) The t-PA variants exhibit comparable catalytic activity to substrates, such as plasminogen, in the presence of co-factors, such as fibrin; and 6) In view of the proceeding properties, the t-PA variants thus are effective at local fibrinolysis function without extensive systemic proteolysis thereby negating the depletion of circulating fibrinogen, α2-anti-plasmin and plasminogen, as is seen with wild type human single chain t-PA precursor.

Preferred recombinant expressed t-PA variants thus include R275E,H417D, R275E,H417E and R275E,K429Y, and conservative substitutions thereof. In general, examples of conservative substitutions include the substitution of one non-polar (hydrophobic) residue such as isoleucine, valine, leucine or methionine for another, the substitution of one polar (hydrophilic) residue for another such as between arginine and lysine, between glutamine and asparagine, between glycine and serine, the substitution of one basic residue such as lysine, arginine or histidine for another, or the substitution of one acidic residue, such as aspartic acid or glutamic acid for another. For further discussion of the classifications of

amino acids see Lehninger, A.L., Biochemistry, 2nd Edition, Worth Publishers, New York, 1975, pp.71-94.

The phrase "conservative substitution" also includes the use of a chemically derivatized residue in place of a non-derivatized residue provided that such protein displays the requisite binding activity. "Chemical derivative" refers to a subject protein having one or more residues chemically derivatized by reaction of a functional side group. Such derivatized molecules include for example, those molecules in which free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Free carboxyl groups may be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides. Free hydroxyl groups may be derivatized to form O-acyl or O-alkyl derivatives. The imidazole nitrogen of histidine may be derivatized to form N-im-benzylhistidine. Also included as chemical derivatives are those peptides which contain one or more naturally occurring amino acid derivatives of the twenty standard amino acids. For example, 4-hydroxyproline may be substituted for proline; 5-hydroxylysine may be substituted for lysine; 3-methylhistidine may be substituted for histidine; homoserine may be substituted for serine; and ornithine may be substituted for lysine. D-amino acids may also be included in place of one or more L-amino acids.

In the specific case of the present invention, basic amino acids, i.e., arginine, lysine and histidine are replaced with non-basic amino acids. Preferably basic amino acids are replaced with polar or acidic amino acids, i.e. amino acid residues chosen from the group consisting of glycine, serine, threonine, asparagine, tyrosine, glutamine, aspartic acid and glutamic acid. Conservative substitutions are thus defined, for the purpose of the present invention, as meaning that non-basic amino acids replacing particular basic amino acids in mature wild type human t-PA may be chosen from the group of non-basic amino acids generally, preferably from the group consisting of glycine, serine, threonine, asparagine, tyrosine, glutamine, aspartic acid and glutamic acid, and more preferably from the group consisting of tyrosine, aspartic acid and glutamic acid, For example, the use of aspartic acid instead of glutamic acid to replace an histidine residue is a conservative substitution. Preferred variants are R275E,H417D and R275E,H417E, described in Example 1 and the R275E,K429Y variant, described in Example 2.

The expressed recombinant t-PA variants having at least two amino acid substitutions, e.g., R275E,H417D, R275E,H417E and R275E,K429Y, further exhibit unique properties. R275E and R275E,H417E are activated by both fibrinogen and fibrin while R275E,K429Y is activated primarily by fibrin and is not sensitive to fibrinogen. The latter is also more resistant than the R275E,H417D and R275E,H417E variants to inhibition by PAI-1. These characteristics provide additional advantages in administering the compounds as therapeutic thrombolytic compositions as further described below. In addition, the t-PA variants described herein are useful in diagnostic applications as described below.

Methods of making and Using t-PA Variant Compositions

Methods of Making

The t-PA variant cDNA and recombinant expressed variant proteins described above are useful in a number of methodological aspects as described in Examples 1 and 2. In particular, the isolated cDNA clones are useful in an expression vector system to produce encoded t-PA variant proteins of this invention. Thus, expression vector systems having a t-PA variant cDNA operably linked therein, including cells containing the expression vectors, are contemplated for generating the recombinant expressed variant proteins of this invention.

Diagnostic Applications

Preferred diagnostic methodological aspects are described herein. In particular, the recombinant expressed t-PA variants of the present invention are useful in diagnostic assays to detect fibrin and fibrin degradation products that have altered activities. The assays are thus indicated in thrombotic conditions. Other diagnostic applications, incuding kits comprising antibodies against the t-PA variants are familiar to one of ordinary skill in the art.

Therapeutic Applications

The t-PA variant cDNAs of the present invention are useful in genetic therapeutic applications for use in ameliorating thrombotic disorders including both acute and chronic conditions. Acute conditions include among others both heart attack and stroke while chronic situations include those of arterial and deep vein thrombosis and restenosis. Preferred

therapeutic compositions thus include the cDNA compounds themselves as naked DNA, presented as part of a viral vector delivery system or other vector-based gene expression delivery system, presented in a liposome delivery system and the like.

The recombinant expressed t-PA variant proteins of the present invention are contemplated as thrombolytic therapeutic agents for ameliorating the same conditions outlined above. Based on the individual structural and functional properties of various t-PA variant proteins described above, the selection of the particular t-PA variant is determined by the desired therapeutic outcome. For example, the fibrinogen-mediated activation of endogenous human t-PA is activated by bleeding which then results in a widespread undesired systemic response. Thus, to mediate fibrinolytic processes locally in either an acute or chronic thrombotic condition while simultaneously preventing proteolytic activation systemically, one would therefore use the t-PA variant, namely R275E,K429Y, that is primarily activated by fibrin and not fibrinogen. A composition for use as thrombolytic therapeutic agents generally a physiologically effective amount of the t-PA variant protein in a pharmaceutically suitable excipient. Depending on the mode of administration and the condition to be treated, the thrombolytic therapeutic agents are administered in single or multiple doses. If "bolus" doses are administered, doses of about 0.01 to about 0.6 mg/kg will typically be administered, preferably doses of about 0.05 to about 0.2 mg/kg, with subsequent administrations of about 0.1 to about 0.2 mg/kg to maintain a t-PA blood level of about 3 microgram/ml. One skilled in the art will appreciate that variations in dosage depend on the condition to be treated. In other applications, a composition of variant t-PA in a gel composition is useful in preventing the formation of adhesions.

Other variations and uses of the present invention will be apparent to one skilled in the art.

Example 1

Site Directed Mutagenesis And Construction Of Expression Vectors Encoding Variants Of T-PA

Oligonucleotide directed site specific mutagenesis was performed by the method of Zoller and Smith (Zoller, M. I., and Smith, M. (1984) DNA 3, 479-488) as modified by Kunkel (Kunkel, T. A. (1985) Proc. Natl. Acad. Sci. U.S.A. 82, 488-492). Mutations were introduced into the 290 bp *Sac*I – *Sma*I fragment of cDNA encoding t-PA that had been

previously subcloned into bacteriophage M13mp18. The mutagenic primers had the following nucleotide sequences:

H417D: 5' – CTACGGCAAGGACGAGGCCTTGT – 3' (SEQ ID NO: 8)

H417E: 5' – CTACGGCAAGGAGGAGGCCTTGT – 3' (SEQ ID NO: 9)

Following mutagenesis, ssDNA corresponding to the entire 290 bp *Sac*I – *Sma*I fragment was fully sequenced to assure the presence of the desired mutation and the absence of any additional mutations. The sequence corresponding to the 290 bp *Sac*I – *Sma*I fragment of the H417D mutation is shown in SEQ ID NO: 5; the corresponding sequence of the H417E mutation is shown in SEQ ID NO: 6. Replicative form (RF) DNA was prepared for appropriate phage, and the mutated 290 bp *Sac*I – *Sma*I fragments were recovered after digestion of RF DNA with *Sac*I and *Sma*I and electrophoresis of the digestion products on an agarose gel. The isolated, mutated *Sac*I – *Sma*I fragments were used to replace the corresponding fragment in full length cDNAs encoding wild type human t-PA or t-PA/R275E to yield new, full length cDNAs encoding t-PA/H417D; t-PA/H417E; t-PA/R275E,H417D (SEQ ID NO: 1); and t-PA/R275E,H417E (SEQ ID NO: 2).

Expression of enzymes by transient transfection of COS cells.

cDNAs encoding t-PA; t-PA/R275E; t-PA/H417D; t-PA/H417E; t-PA/R275E,H417D; and t-PA/R275E were ligated into the transient expression vector pSVT7 which is described in Madison, E. L., et al. (1989) *Nature* **339**, 721-724; Bird, P.M., et al., (1987) *J. Cell Biol.* **105:** 2905-2914; and Sambrook, J., et al., (1986) *Mol. Biol. Med.* **3:** 459-481. See also U.S. Pat. No. 5,550,042, incorporated herein by reference, which describes the construction and use of pSVT7 as well as the deposit with American Type Culture Collection, 12301 Parklawn Dr., Rockville, MD 20852 of cultures comprising other pSVT7 t-PA constructs. Vectors with ligated cDNA inserts were then introduced into COS 1 cells by electroporation using a Bio Rad Gene Pulser. An aliquot containing 20 μg of cDNA, 100 μg of carrier DNA and approximately 10^7 COS cells were placed into a 0.4 cm cuvette, and electroporation was performed at 320 V, 960 μFD, and $\Omega = \infty$. Following electroporation, cells were incubated overnight at 37 degrees Celsius in DMEM containing 10% fetal calf serum and 5 mM sodium butyrate. Cells were then washed with serum free medium and incubated in DMEM for 48 hours at 37 degrees Celsius. After the incubation with serum free media, conditioned media

were collected. Enzyme concentrations in aliquots of the the collected conditioned media were determined by ELISA.

Kinetic analysis of plasminogen activation using indirect chromogenic assays.

Indirect chromogenic assays of t-PA utilized the substrates lys-plasminogen (American Diagnostica, Greenwich, CT) and Spectrozyme PL (American Diagnostica) and were performed as previously described (Madison, E. L., Goldsmith, E. J., Gerard, R. D., Gething, M.-J., and Sambrook, J. F. (1989) *Nature* **339**, 721-724; Madison, E. L., Goldsmith, E. J., Gerard, R. D., Gething, M. J., Sambrook, J. F., and Bassel-Duby, R. S. (1990) *Proc. Natl. Acad. Sci. U.S.A.* **87**, 3530-3533; Madison, E. L., Goldsmith, E. J., Gething, M. J., Sambrook, J. F., and Gerard, R. D. (1990) *J. Biol. Chem.* **265**, 21423-21426.). Assays were performed both in the presence and absence of the co-factor DESAFIB (American Diagnostica). The concentration of lys-plasminogen was varied from 0.0125 – 0.2 μM in the presence of DESAFIB and from 0.9 – 15 μM in the absence of the co-factor.

Kinetic analysis of t-PA activity using a small, synthetic substrate

The direct chromogenic assay utilized the substrate methylsulfonyl-D-cyclohexyltyrosyl-glycyl-arginine-p-nitroaniline (Spectrozyme t-PA, American Diagnostica) and was performed as previously described (Strandberg, L., and Madison, E. L. (1995) *J. Biol. Chem.* **270**, 23444-23449; Smith, J. W., Tachias, K., and Madison, E. L. (1995) *J. Biol. Chem.* **270**, 30486-30490).

Measurement of second order rate constants for inhibition by PAI-1

Second order rate constants for the inhibition of wild type human t-PA and variant t-PA were measured under pseudo-first order conditions as previously described. Briefly, enzyme and inhibitor were preincubated at 23 degrees Celsius for periods of time varying from 0 – 30 minutes. Following preincubation, the mixtures were diluted, and the residual enzymatic activity was measured in a standard indirect chromogenic assay. For each enzyme, the concentrations of enzyme and inhibitor and the times of preincubation were chosen to yield several data points for which the residual enzymatic activity varied between 20% and 80% of

the initial activity. Data were analyzed by plotting the natural logarithm of the ratio (residual activity/initial activity) versus time of preincubation and measuring the resulting slopes. Division of this slope by -[I] yielded the second order rate constants shown.

It was found that replacement of histidine 417 of t-PA with an acidic residue selectively suppresses the catalytic activity of single chain t-PA. Histidine 417 was replaced by either an aspartate or glutamate residue to yield two variants: t-PA/H417D and t-PA/H417E. Accurate measurement of the enzymatic activity toward plasminogen of the single chain form of these two variants proved difficult, however, because the plasmin produced in this assay rapidly converted the single chain enzymes into their mature, two-chain form by cleaving the R275-I276 peptide bond. Consequently, to overcome this technical difficulty, we also constructed noncleavable forms of the two mutated enzymes by introducing the additional mutation R275E into the existing mutants.

Wild type human t-PA, t-PA/R275E, and all four variants containing mutations at position 417 were expressed by transient expression of COS-1 cells. Since this procedure yielded predominantly single chain enzymes, two-chain t-PAs were generated by treating the enzyme preparations with plasmin-Sepharose (Strandberg, L., and Madison, E. L. (1995) *J. Biol. Chem.* **270**, 23444-23449). Quantitative conversion of the enzymes into their mature, two-chain form was confirmed by SDS-PAGE. As expected, variants containing the mutation R275E were synthesized and secreted exclusively as single chain enzymes and were not cleaved by plasmin-Sepharose.

The enzymatic activity of the single and two-chain forms of wild type human t-PA and each variant toward a small synthetic substrate is listed in Table I below. Mutation of histidine 417 had only very modest effects on the activity of the two-chain enzymes. Two-chain t-PA/H417D and t-PA/H417E displayed 67% or 80%, respectively, the activity of the two-chain, wild type human t-PA enzyme in this assay. The H417D and H417E mutations, however, had more significant effects on the activities of the single chain enzymes. Compared to single chain t-PA/R275E, single chain t-PA/R275E,H417D (SEQ ID NO: 1) and t-PA/R275E,H417E (SEQ ID NO: 2) exhibited approximately 16% or 25%, respectively, the activity of single chain t-PA/R275E.

Table 1

Kinetic constants for cleavage of the chromogenic substrate Spectrozyme t-PA by single- and two-chain t-PA variants

Enzyme	K_{cat} (s^{-1})	K_m (mM)	K_{cat}/K_m ($M^{-1}s^{-1}$)
Two-chain form			
t-PA	59	0.4	$1.5x10^5$
t-PA/H417D	41	0.4	$1.0x10^5$
t-PA/H417E	58	0.5	$1.2x10^5$
Single-chain form			
t-PA/R275E	26	0.7	$3.7x10^4$
t-PA/R275E,H417D	5.9	1.0	$5.9x10^3$
t-PA/R275E,H417E	12	1.3	$9.2x10^3$

All of the variants analyzed maintained high enzymatic activity towards the natural substrate, plasminogen, in the presence of the co-factor fibrin (Table II below). The catalytic activity of the two-chain form of wild type human t-PA, t-PA/H417D, and t-PA/H417E varied by a factor of only 1.4. Similarly, the activities of single chain t-PA/R275E, t-PA/R275E,H417D, and t-PA/R275E,H417E differed by a factor of less than 1.8.

Table II

Kinetic constants for activation of plasminogen by single- and two-chain t-PA variants in the presence of fibrin

Enzyme	K_{cat} (s^{-1})	K_m (μM)	K_{cat}/K_m ($M^{-1}s^{-1}$)
Two-chain form			
t-PA	0.11	0.017	$6.5x10^6$
t-PA/H417D	0.11	0.024	$4.6x10^6$
t-PA/H417E	0.10	0.022	$4.5x10^6$
Single-chain form			
t-PA/R275E	0.16	0.017	$9.4x10^6$
t-PA/R275E,H417D	0.23	0.043	$5.3x10^6$
t-PA/R275E,H417E	0.17	0.028	$6.1x10^6$

In the absence of a co-factor, the mutations at position 417 had little effect on the activity of two-chain t-PA toward plasminogen; however, these mutations significantly reduced the catalytic efficiency of single chain t-PA (Table III below). Compared to that of single chain t-PA/R275E, the activity of t-PA/R275E,H417D and t-PA/R275E,H417E was reduced by a factor of approximately 14 or 6, respectively. In this assay, the "zymogenicity", or ratio of the activities of the two-chain and single chain form of a particular enzyme, were approximately 9 for wild type t-PA. By contrast, for variants containing the H417D or H417E mutation, this ratio increased to approximately 150 or 50, respectively (Table III).

Table III

Kinetic constants for activation of plasminogen by single- and two-chain variants of t-PA in the absence of a cofactor

Enzyme	$K_{cat}(s^{-1})$	$K_m(\mu M)$	$K_{cat}/K_m(M^{-1}s^{-1})$
Two-chain form			
t-PA	0.093	6.7	$1.4x10^4$
t-PA/H417D	0.110	6.8	$1.6x10^4$
t-PA/H417E	0.099	8.7	$1.1x10^4$
Single-chain form			
t-PA/R275E	0.014	9.5	$1.5x10^3$
t-PA/R275E,H417D	0.001	9.4	$1.1x10^2$
t-PA/R275E,H417E	0.002	8.5	$2.4x10^2$

Molecular details of the stimulation of t-PA by fibrin, a complex process that almost certainly involves multiple points of contact between the two proteins, remain unclear. While fibrin stimulation of two-chain t-PA may occur through a single mechanism; stimulation of single chain t-PA by fibrin co-factors, however, appears to utilize at least two distinct mechanisms. First, fibrin apparently stimulates both single- and two-chain t-PA through a templating mechanism resulting in formation of a ternary complex which greatly augments the local concentration of enzyme and substrate. Second, because single- and two-chain t-Pa have equivalent activity in the presence but not the absence of fibrin, it seems likely that binding to fibrin induces a conformational change in the activation domain of single chain t-PA. Similar activation of plasminogen upon binding to streptokinase as well as activation of prothrombin

by binding to staphylocoagulase have been described previously. Although the mechanism of this nonclassical, nonproteolytic activation of serine protease zymogens remains completely unclear, the behavior of single chain t-PA/R275E,H417D and t-PA/R275E,H417E indicates that His 417 does not play an essential role in this process. In addition, the properties of two-chain t-PA/H417D and t-PA/H417E indicate that His 417 does not play an essential role during zymogen activation of t-PA through the classical, proteolytic mechanism.

The primary effect of the H417D and H417E mutations was a selective reduction of the activity of single chain t-PA in the absence of fibrin and, consequently, an increase in the zymogenicity of the enzyme. At the molecular level this effect could be mediated either by stabilizing a less active, new conformation of single chain t-PA or by shifting the equilibrium between one or more existing conformations, with distinct activities, towards the less active conformation. Without being held to a single hypothesis, based on structural studies of trypsinogen, trypsin, chymotrypsinogen, and chymotrypsin, that the existence of an equilibrium among multiple conformations of the activation domain is likely to be a general feature of chymotrypsinogen family zymogens.

It is believed that the effect produced by converting His 417 to an acidic residue is mediated by disrupting the important salt bridge between Asp 477 and Lys 429 by providing an alternative, electrostatic interaction for Lys 429. The observation of an electrostatic interaction between K429 and E417 in the recently reported structure of the protease domain of two-chain u-PA, although the distance and geometry of this interaction vary somewhat in the two members of the unit cell in this study, lends credence to this hypothesis. Moreover, as observed in this study, formation of a new salt bridge between Lys 429 and Asp/Glu 417 would be expected to selectively suppress the activity of single chain t-PA because Lys 429 does not interact with Asp 477 in the two-chain enzyme. Instead, in two-chain t-PA, as in other mature chymotrypsin like enzymes, the mature amino terminus inserts into the activation pocket and plays this role. Consequently, as observed, two-chain t-PA/H417D and t-PA/H417E are expected to maintain high catalytic activity. Variants of t-PA containing an acidic residue at position 417, therefore, exhibit significantly enhanced zymogenicity.

Table IV

Stimulatory effect of fibrin on the catalytic efficiencies for variants of t-PA

Enzyme	Fold stimulation of k_{cat}/K_m
Two-Chain form	
t-PA	460
t-PA/H417D	290
t-PA/H417E	410
Single-chain form	
t-PA/R275E	6300
t-PA/R275E,H417D	48,200
t-PA/R275E,H417E	25,400

The extent of fibrin stimulation displayed by the single chain form of the mutated enzymes examined in this study is significantly greater than that displayed by wild type t-PA. Wild type, two-chain t-PA possesses a fibrin stimulation factor, defined as the ratio of the catalytic efficiencies in the presence and absence of fibrin, of approximately 460 (Table IV above). The two-chain variants display similar stimulation factors of 290 (t-PA/H417D) and 410 (t-PA/H417E). Single chain wild type t-PA, with a fibrin stimulation factor of 6300, is stimulated to a substantially greater degree than the two-chain enzymes, presumable reflecting the ability of fibrin to stimulate the single chain enzymes not only through a templating mechanism but also by inducing nonproteolytic zymogen activation. Stimulation of single chain t-PA is further enhanced by the H417D or H417E mutations. The fibrin stimulation factors for single chain t-PA/R275E,H417D and t-PA/H417E are 48,200 and 25,400, respectively (Table IV above). Enhanced fibrin stimulation of the variants did not result from increased activity in the presence of fibrin but rather from decreased activity in the absence of a stimulator, an observation consistent with the belief that the effects of these mutations are mediated by disruption of a salt bridge between Lys 429 and Asp 477 in single chain t-PA.

The single chain form of a zymogen-like variant of t-PA is expected to exhibit reduced activity not only towards substrates (Tables I and III, above) but also towards specific inhibitors. To demonstrate this, we measured the second order rate constant for inhibition of

single chain t-PA/R275E, t-PA/R275E,H417D, and t-PA/R275E,H417E by the serpin plasminogen activator inhibitor, type 1 (PAI-1) (Table V below). As expected, both variants containing mutations at position 417 exhibited resistance to inhibition by PAI-1. The second order rate constant for inhibition by PAI-1 of t-PA/R275E,H417D or t-PA/R275E,H417E was reduced by factors of approximately 12 or 9, respectively, compared with t-PA/R275E.

Table V

Inhibition of wild type and variants of t-PA by PAI-1

Enzyme	Second Order Rate Constant ($M^{-1}s^{-1}$)
t-PA/R275E	$1.8x10^6$
t-PA/R275E,H417D	$1.5x10^5$
t-PA/R275E,H417E	$2.1x10^5$

t-PA exhibits unusually high catalytic activity as a single chain enzyme and consequently very low zymogenicity. By contrast, a closely related enzyme urokinase (u-PA) exhibits much lower catalytic activity as a single chain enzyme and substantially higher zymogenicity. An important finding of this study is that the presence or absence of a favorable electrostatic interaction between residues at positions 417 and 429 appears to be the major determinant of this key functional distinction between the two human plasminogen activators. The zymogenicity of wild type t-PA, u-PA, and t-PA containing an aspartate at position 417 are approximately 9, 250, and 150, respectively.

These studies demonstrated structure/function relationships within the activation domain of t-PA, and elucidated the molecular basis of important functional distinctions between t-PA and u-PA. These results can also aid the design of improved thrombolytic agents. For example t-PA/R275E,H417D, exhibits substantially enhanced fibrin stimulation, resistance to inhibition by PAI-1, and significantly increased zymogenicity, a useful combination of properties that enhances the therapeutic utility of the enzyme.

Example 2

Site Directed Mutagenesis And Construction Of Expression Vectors Encoding Variants Of T-PA.

Oligonucleotide directed site specific mutagenesis was performed as described in Example 1. The K429Y mutation was introduced into the 290 bp *SacI – SmaI* fragment of cDNA encoding t-PA that had been previously subcloned into bacteriophage M13mp18. The mutagenic primer had the following nucleotide sequence:

5' – CGGAGCGGCTGTATGAGGCTCATGT – 3' (SEQ ID NO: 10).

Following mutagenesis, ssDNA corresponding to the entire 290 bp *SacI – SmaI* fragment was fully sequenced to assure the presence of the desired mutation and the absence of any additional mutations. The sequence corresponding to the 290 bp *Sac*I – *Sma*I fragment of the K429Y mutation is shown in SEQ ID NO: 7. Replicative form (RF) DNA was prepared for appropriate phage, and the mutated 290 bp *SacI – SmaI* fragment was recovered after digestion of RF DNA with *SacI* and *SmaI* and electrophoresis of the digestion products on an agarose gel. The isolated, mutated *SacI – SmaI* fragment was used to replace the corresponding fragment in full length cDNAs encoding wild type t-PA or t-PA/R275E to yield new, full length cDNAs encoding t-PA/K429Y and t-PA/R275E,K429Y.

Expression of enzymes by transient transfection of COS cells.

cDNAs encoding t-PA, t-PA/R275E, t-PA/K429Y, and t-PA/R275E,K429Y were ligated into the transient expression vector pSVT7 and then introduced into COS cells by electroporation using a Bio Rad Gene pulser as described in Example 1. Following electroporation, cells were incubated overnight at 37 degrees Celsius in DMEM containing 10% fetal calf serum and 5mM sodium butyrate. Cells were then washed with serum free medium and incubated in DMEM for 48 hours at 37 degrees Celsius. After the incubation with serum free media, conditioned media were collected and enzyme concentrations were determined by ELISA.

Purification of wild type and mutated variants of t-PA.

Wild type and mutated variants of t-PA were purified using an FPLC system and a 1 ml HiTrap chelating column (Pharmacia Biotech). The column was charged with 0.1 M

$CuSO_4$ solution, washed with 5 – 10 ml distilled water, and equilibrated with start buffer (0.02 M $NaHPO_4$, pH 7.2, 1 M NaCl and 1 mM Imidizole). Conditioned medium containing wild type or variants of t-PA was adjusted to 1 M NaCl and injected into the column with a 50 ml superloop (Pharmacia Biotech). The column was then washed with 10 column volumes of start buffer and eluted using a 0 – 0.32 M linear gradient of imidizole in the same buffer. Peak fractions were collected and pooled. Purified t-PA samples were concentrated, and buffer was exchanged to 25 mM Tris (pH = 7.5), 50 mM NaCl, 1 mM EDTA, using a Centriplus 30 concentrator (Amicon).

Kinetic analysis of t-PA activity using a small, synthetic substrate.

The direct chromogenic assay utilized the substrate methylsulfonyl-D-cyclohexyltyrosyl-glycyl-arginine-p-nitroaniline (Spectrozyme t-PA, American Diagnostica) and was performed as described in Example 1.

Kinetic analysis of plasminogen activation using indirect chromogenic assays.

Indirect chromogenic assays of t-PA utilized the substrates lys-plasminogen (American Diagnostica) and Spectrozyme PL (American Diagnostica) and were performed as previously described in Example 1. Assays were performed both in the presence and absence of the co-factor DESAFIB (American Diagnostica).

Indirect Chromogenic Assays in the presence of Various Fibrin Co-factors.

Standard indirect chromogenic assays were performed. Briefly, 0.25 – 1ng of enzyme, 0.2 μM lys-plasminogen and 0.62 mM Spectrozyme PL were present in a total volume of 100 μl. Assays were performed either in the presence of buffer, 25 μg/ml DESAFIB, 100 μg/ml fibrinogen, 100 μg/ml cyanogen bromide fragments of fibrinogen (American Diagnostica), or 100 μg/ml of the stimulatory, thirteen amino acid peptide P368. P368 was kindly provided by Marshall Runge (University of Texas Medical Center, Galveston, TX.). Assays were performed in microtiter plates, and the optical density at 405 nm was measured every 30 seconds for one hour in a Molecular Devices Thermomax. Reactions were performed at 37 degrees Celsius.

Measurement of second order rate constants for inhibition by PAI-1.

Second order rate constants for the inhibition of wild type and mutated t-PA were measured under pseudo-first order conditions as described in Example 1.

Oligonucleotide directed site specific mutagenesis was used to produce a mutation of Lys 429 of t-PA that selectively suppressed the catalytic activity of single chain t-PA. Lysine 429 was replaced by a tyrosine residue to yield t-PA/K429Y. In addition, to permit accurate measurement of the enzymatic activity toward plasminogen of the single chain form of this variant, a noncleavable form of the mutated enzyme was constructed by introducing the additional mutation R275E into the existing mutant to yield the R275E,K429Y variant.

Wild type t-PA, t-PA/R275E, t-PA/K429Y, and t-PA/R275E,K429Y were expressed by transient expression in COS 1 cells as described in Example 1. Since this procedure yielded predominantly single chain enzymes, two-chain t-PAs were generated by treating the enzyme preparations with plasmin-Sepharose. Quantitative conversion of the enzymes into their mature, two-chain form was confirmed by SDS-PAGE. As previously demonstrated, variants containing the mutation R275E were synthesized and secreted exclusively as single chain enzymes and were not cleaved by plasmin-Sepharose.

Table VI

Kinetic constants for cleavage of the chromogenic substrate Spectrozyme t-PA by single- and two-chain t-PA variants

Enzyme	$K_{cat}(s^{-1})$	K_m(mM)	$K_{cat}/K_m(M^{-1}s^{-1})$
Two-chain form			
t-PA	40	0.5	$8.0x10^4$
t-PA/K429Y	35	0.5	$7.0x10^4$
Single-chain form			
t-PA/R275E	24	0.7	$3.4x10^4$
t-PA/R275E,K429Y	0.3	0.5	$6.0x10^2$

The enzymatic activity of the single and two-chain forms of wild type and t-PAs toward a small synthetic substrate is listed in Table VI above. Mutation of lysine 429 had little effect on the activity of two-chain t-PA. Two-chain t-PA/K429Y displayed approximately

90% of the activity of the two-chain, wild type enzyme in this assay. By contrast, the K429Y mutation had a very substantial effect on the activity of single chain t-PA. Single chain t-PA/R275E,K429Y exhibited approximately 2% of the activity of single chain t-PA/R275E. In this assay, the zymogenicity, defined as the ratio of the activities of the two-chain to that of the single chain form of a particular enzyme, was approximately 2.5 for wild type t-PA. By contrast, for variants containing the K429Y mutation, this ratio increased to approximately 117 (Table VI).

In the absence of a co-factor, the K429Y mutation had little effect on the activity of two-chain t-PA toward plasminogen; however, this mutation significantly reduced the catalytic efficiency of single chain t-PA (Table VII below). Compared with that of single chain t-PA/R275E, the activity of single chain t-PA/R275E,K429Y was reduced by a factor of 17. By contrast, the activities of two-chain t-PA and t-PA/K429Y differed by a factor of only 1.2.

Table VII

Kinetic constants for activation of plasminogen by single- and two-chain variants of t-PA in the absence of a cofactor

Enzyme	$K_{cat}(s^{-1})$	$K_m(\mu M)$	$K_{cat}/K_m(M^{-1}s^{-1})$
Two-chain form			
t-PA	0.16	10	$1.6x10^4$
t-PA/K429Y	0.18	14	$1.3x10^4$
Single-chain form			
t-PA/R275E	[0.038]	[30]	$1.3x10^3$
t-PA/R275E,K429Y	0.00046	5.9	$7.8x10^1$

All of the variants analyzed in this study maintained reasonably high enzymatic activity towards the natural substrate plasminogen in the presence of the co-factor fibrin (Table VIII below). The single chain form of variants containing the K429Y mutation were, however, affected to a slightly greater extent than the corresponding mature, two-chain enzymes. Two-chain t-PA/K429Y possessed approximately 75% of the activity of two-chain t-PA while single chain t-PA/R275E,K429Y exhibited approximately 40% of the activity of single chain t-PA/R275E.

Table VIII

Kinetic constants for activation of plasminogen by single- and two-chain t-PA variants in the presence of fibrin

Enzyme	$K_{cat}(s^{-1})$	$K_m(\mu M)$	$K_{cat}/K_m(M^{-1}s^{-1})$
Two-chain form			
t-PA	0.08	0.02	$4.0x10^6$
t-PA/K429Y	0.08	0.03	$3.0x10^6$
Single-chain form			
t-PA/R275E	0.10	0.02	$5.0x10^6$
t-PA/R275E,K429Y	0.10	0.07	$2.0x10^6$

The extent of fibrin stimulation displayed by the single chain form of t-PA/R275E,K429Y is significantly greater than that displayed by wild type t-PA. Wild type, two-chain t-PA possesses a fibrin stimulation factor, defined as the ratio of the catalytic efficiencies in the presence and absence of fibrin, of approximately 250 (Table IX below). The two-chain t-PA/K429Y variant displays a similar stimulation factor of 230. Single chain wild type t-PA, with a fibrin stimulation factor of 3800, is stimulated to a substantially greater degree than the two-chain enzymes, presumable reflecting the ability of fibrin to stimulate the single chain enzymes not only through a templating mechanism but also by inducing nonproteolytic zymogen activation. Stimulation of single chain t-Pa is further enhanced by the K429Y mutation. The fibrin stimulation factor for single chain t-PA/R275E,K429Y is approximately 26,000. Enhanced fibrin stimulation of the variant did not result from increased activity in the presence of fibrin but rather from decreased activity in the absence of a stimulator, an observation consistent with our proposal that the effects of these mutations are mediated by disruption of a salt bridge between Lys 429 and Asp 477 in single chain t-PA.

Table IX

Stimulatory effect of fibrin on the catalytic efficiencies for variants of t-PA

Enzyme	Fold stimulation of k_{cat}/K_m
Two-chain form	
t-PA	250
t-PA/K429Y	230
Single-chain form	
t-PA/R275E	3800
t-PA/R275E,K429Y	26,000

The mutated enzyme t-PA/R275E,K429Y is not only stimulated to a significantly greater extent by soluble fibrin than t-PA (Table IX above), but it is also substantially more discriminating among fibrin co-factors than the wild type enzyme (Fig. 2). The two-chain form of both wild type t-PA and t-PA/K429Y are strongly stimulated by soluble fibrin monomers (DESAFIB), fibrinogen, CNBr fragments of fibrinogen, and a 13 amino acid peptide (P368). Single chain t-PA/R275E, on the other hand, is stimulated strongly by soluble fibrin and fibrinogen and moderately by the CNBr fragments and peptide P368. In striking contrast to these enzymes, single chain t-PA/R275E,K429Y, although dramatically stimulated by fibrin monomers, is virtually nonresponsive to fibrinogen, CNBr fragments of fibrinogen, peptide P368.

The ratio of the specific activity of a plasminogen activator in the presence of fibrin to that in the presence of fibrinogen, or "fibrin selectivity factor", is one indication of the "clot selectivity" an enzyme will demonstrate in vivo. An enzyme with enhanced fibrin selectivity can accomplish efficient thrombolysis while displaying decreased systemic activity. Under the conditions of the assays reported here, the fibrin selectivity is 1.5 for two-chain t-PA, 1.5 for two-chain t-PA/K429Y, and 1.0 for single chain t-PA/R275E. The fibrin selectivity factor for single chain t-PA/R275E,K429Y, however, is 146. This double mutant, therefore, is approximately two orders of magnitude more discriminating between fibrin and fibrinogen than either single or two-chain wild type t-PA.

The single chain form of a zymogen-like variant of t-PA is expected to exhibit reduced activity not only towards substrates (Tables VI and VIII above) but also towards specific

inhibitors. The second order rate constant for inhibition of the single chain form of both t-PA/R275E and t-PA/R275E,K429Y by the serpin plasminogen activator inhibitor, type 1 (PAI-1), the primary physiological inhibitor of t-PA is shown in Table X below. As expected, t-PA/R275E,K429Y exhibited resistance to inhibition by PAI-1. The second order compared with t-PA/R275E.

Table X

Inhibition of wild type and variants of t-PA by PAI-1

Enzyme	Second order rate constant ($M^{-1}s^{-1}$)
t-PA/R275E	$1.8x10^6$
t-PA/R275E,K429Y	$7.7x10^3$

An important finding of this study is that conversion of lysine 429 to tyrosine residue selectively suppresses the activity of single chain t-PA and thereby substantially enhances the zymogenicity of the enzyme. We have demonstrated, in addition, that single chain t-PA/R275E,K429Y is significantly more fibrin stimulated and substantially more fibrin selective than either single or two-chain, wild type t-PA. Single chain t-PA/R275E,K429Y also exhibits marked resistance to inhibition by PAI-1. It is believed that the effects of this mutation are mediated by disruption of a critical salt bridge formed by Lys 429 and Asp 477 that has been predicted to be present in single- but not two-chain t-PA. The primary role of this putative salt bridge is believed to be stabilization of the active conformation of single chain t-PA. Two-chain t-PA/K429Y, therefor, as demonstrated in this study, is expected to maintain high enzymatic activity.

These results aid in the design of improved thrombolytic agents. For Example t-PA/R275E,K429Y, exhibits significantly enhanced fibrin stimulation, dramatically increased discrimination among fibrin co-factors, marked resistance to inhibition by PAI-1, and substantially increased zymogenicity, a combination of properties that enhance the therapeutic utility of the enzyme.

The foregoing is intended to be illustrative of the present invention, but not limiting. Numerous variations and modifications of the present invention may be effected without departing from the true spirit and scope of the invention.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Madison, Edwin L

(ii) TITLE OF INVENTION: TISSUE TYPE PLASMINOGEN ACTIVATOR (t-PA) VARIANTS HAVING ZYMOGEN CHARACTERISTICS: COMPOSITIONS AND METHODS OF USE

(iii) NUMBER OF SEQUENCES: 1

(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: McDonnell Boehnen Hulbert & Berghoff
(B) STREET: 300 South Wacker Drive, 32nd Floor
(C) CITY: Chicago
(D) STATE: IL
(E) COUNTRY: USA
(F) ZIP: 60606

(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Zimmerman, Roger P
(B) REGISTRATION NUMBER: 38,670
(C) REFERENCE/DOCKET NUMBER: 97,707

(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 312-913-0001
(B) TELEFAX: 312-913-0002

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 527 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
Ser Tyr Gln Val Ile Cys Arg Asp Glu Lys Thr Gln Met Ile Tyr Gln
1               5                  10                  15

Gln His Gln Ser Trp Leu Arg Pro Val Leu Arg Ser Asn Arg Val Glu
            20                  25                  30

Tyr Cys Trp Cys Asn Ser Gly Arg Ala Gln Cys His Ser Val Pro Val
        35                  40                  45

Lys Ser Cys Ser Glu Pro Arg Cys Phe Asn Gly Gly Thr Cys Gln Gln
    50                  55                  60

Ala Leu Tyr Phe Ser Asp Phe Val Cys Gln Cys Pro Glu Gly Phe Ala
65                  70                  75                  80

Gly Lys Cys Cys Glu Ile Asp Thr Arg Ala Thr Cys Tyr Glu Asp Gln
                85                  90                  95

Gly Ile Ser Tyr Arg Gly Thr Trp Ser Thr Ala Glu Ser Gly Ala Glu
            100                 105                 110

Cys Thr Asn Trp Asn Ser Ser Ala Leu Ala Gln Lys Pro Tyr Ser Gly
        115                 120                 125

Arg Arg Pro Asp Ala Ile Arg Leu Gly Leu Gly Asn His Asn Tyr Cys
    130                 135                 140

Arg Asn Pro Asp Arg Asp Ser Lys Pro Trp Cys Tyr Val Phe Lys Ala
145                 150                 155                 160

Gly Lys Tyr Ser Ser Glu Phe Cys Ser Thr Pro Ala Cys Ser Glu Gly
                165                 170                 175

Asn Ser Asp Cys Tyr Phe Gly Asn Gly Ser Ala Tyr Arg Gly Thr His
            180                 185                 190

Ser Leu Thr Glu Ser Gly Ala Ser Cys Leu Pro Trp Asn Ser Met Ile
        195                 200                 205

Leu Ile Gly Lys Val Tyr Thr Ala Gln Asn Pro Ser Ala Gln Ala Leu
    210                 215                 220

Gly Leu Gly Lys His Asn Tyr Cys Arg Asn Pro Asp Gly Asp Ala Lys
225                 230                 235                 240

Pro Trp Cys His Val Leu Lys Asn Arg Arg Leu Thr Trp Glu Tyr Cys
                245                 250                 255

Asp Val Pro Ser Cys Ser Thr Cys Gly Leu Arg Gln Tyr Ser Gln Pro
            260                 265                 270

Gln Phe Glu Ile Lys Gly Gly Leu Phe Ala Asp Ile Ala Ser His Pro
        275                 280                 285

Trp Gln Ala Ala Ile Phe Ala Lys His Arg Arg Ser Pro Gly Glu Arg
```

```
    290                 295                 300
Phe Leu Cys Gly Gly Ile Leu Ile Ser Ser Cys Trp Ile Leu Ser Ala
305                 310                 315                 320

Ala His Cys Phe Gln Glu Arg Phe Pro Pro His His Leu Thr Val Ile
                325                 330                 335

Leu Gly Arg Thr Tyr Arg Val Val Pro Gly Glu Glu Glu Gln Lys Phe
            340                 345                 350

Glu Val Glu Lys Tyr Ile Val His Lys Glu Phe Asp Asp Asp Thr Tyr
        355                 360                 365

Asp Asn Asp Ile Ala Leu Leu Gln Leu Lys Ser Asp Ser Ser Arg Cys
    370                 375                 380

Ala Gln Glu Ser Ser Val Val Arg Thr Val Cys Leu Pro Pro Ala Asp
385                 390                 395                 400

Leu Gln Leu Pro Asp Trp Thr Glu Cys Glu Leu Ser Gly Tyr Gly Lys
                405                 410                 415

Asp Glu Ala Leu Ser Pro Phe Tyr Ser Glu Arg Leu Lys Glu Ala His
            420                 425                 430

Val Arg Leu Tyr Pro Ser Ser Arg Cys Thr Ser Gln His Leu Leu Asn
        435                 440                 445

Arg Thr Val Thr Asp Asn Met Leu Cys Ala Gly Asp Thr Arg Ser Gly
    450                 455                 460

Gly Pro Gln Ala Asn Leu His Asp Ala Cys Gln Gly Asp Ser Gly Gly
465                 470                 475                 480

Pro Leu Val Cys Leu Asn Asp Gly Arg Met Thr Leu Val Gly Ile Ile
                485                 490                 495

Ser Trp Gly Leu Gly Cys Gly Gln Lys Asp Val Pro Gly Val Tyr Thr
            500                 505                 510

Lys Val Thr Asn Tyr Leu Asp Trp Ile Arg Asp Asn Met Arg Pro
        515                 520                 525
```

2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 527 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```
Ser Tyr Gln Val Ile Cys Arg Asp Glu Lys Thr Gln Met Ile Tyr Gln
1               5                  10                  15

Gln His Gln Ser Trp Leu Arg Pro Val Leu Arg Ser Asn Arg Val Glu
            20                  25                  30

Tyr Cys Trp Cys Asn Ser Gly Arg Ala Gln Cys His Ser Val Pro Val
        35                  40                  45

Lys Ser Cys Ser Glu Pro Arg Cys Phe Asn Gly Gly Thr Cys Gln Gln
    50                  55                  60

Ala Leu Tyr Phe Ser Asp Phe Val Cys Gln Cys Pro Glu Gly Phe Ala
65                  70                  75                  80

Gly Lys Cys Cys Glu Ile Asp Thr Arg Ala Thr Cys Tyr Glu Asp Gln
                85                  90                  95

Gly Ile Ser Tyr Arg Gly Thr Trp Ser Thr Ala Glu Ser Gly Ala Glu
            100                 105                 110

Cys Thr Asn Trp Asn Ser Ser Ala Leu Ala Gln Lys Pro Tyr Ser Gly
        115                 120                 125

Arg Arg Pro Asp Ala Ile Arg Leu Gly Leu Gly Asn His Asn Tyr Cys
    130                 135                 140

Arg Asn Pro Asp Arg Asp Ser Lys Pro Trp Cys Tyr Val Phe Lys Ala
145                 150                 155                 160

Gly Lys Tyr Ser Ser Glu Phe Cys Ser Thr Pro Ala Cys Ser Glu Gly
                165                 170                 175

Asn Ser Asp Cys Tyr Phe Gly Asn Gly Ser Ala Tyr Arg Gly Thr His
            180                 185                 190

Ser Leu Thr Glu Ser Gly Ala Ser Cys Leu Pro Trp Asn Ser Met Ile
        195                 200                 205

Leu Ile Gly Lys Val Tyr Thr Ala Gln Asn Pro Ser Ala Gln Ala Leu
    210                 215                 220

Gly Leu Gly Lys His Asn Tyr Cys Arg Asn Pro Asp Gly Asp Ala Lys
225                 230                 235                 240

Pro Trp Cys His Val Leu Lys Asn Arg Arg Leu Thr Trp Glu Tyr Cys
                245                 250                 255

Asp Val Pro Ser Cys Ser Thr Cys Gly Leu Arg Gln Tyr Ser Gln Pro
            260                 265                 270

Gln Phe Glu Ile Lys Gly Gly Leu Phe Ala Asp Ile Ala Ser His Pro
        275                 280                 285
```

```
Trp Gln Ala Ala Ile Phe Ala Lys His Arg Arg Ser Pro Gly Glu Arg
290                 295                 300

Phe Leu Cys Gly Gly Ile Leu Ile Ser Ser Cys Trp Ile Leu Ser Ala
305                 310                 315                 320

Ala His Cys Phe Gln Glu Arg Phe Pro Pro His His Leu Thr Val Ile
                325                 330                 335

Leu Gly Arg Thr Tyr Arg Val Val Pro Gly Glu Glu Glu Gln Lys Phe
            340                 345                 350

Glu Val Glu Lys Tyr Ile Val His Lys Glu Phe Asp Asp Asp Thr Tyr
        355                 360                 365

Asp Asn Asp Ile Ala Leu Leu Gln Leu Lys Ser Asp Ser Ser Arg Cys
370                 375                 380

Ala Gln Glu Ser Ser Val Val Arg Thr Val Cys Leu Pro Pro Ala Asp
385                 390                 395                 400

Leu Gln Leu Pro Asp Trp Thr Glu Cys Glu Leu Ser Gly Tyr Gly Lys
                405                 410                 415

Glu Glu Ala Leu Ser Pro Phe Tyr Ser Glu Arg Leu Lys Glu Ala His
            420                 425                 430

Val Arg Leu Tyr Pro Ser Ser Arg Cys Thr Ser Gln His Leu Leu Asn
        435                 440                 445

Arg Thr Val Thr Asp Asn Met Leu Cys Ala Gly Asp Thr Arg Ser Gly
450                 455                 460

Gly Pro Gln Ala Asn Leu His Asp Ala Cys Gln Gly Asp Ser Gly Gly
465                 470                 475                 480

Pro Leu Val Cys Leu Asn Asp Gly Arg Met Thr Leu Val Gly Ile Ile
                485                 490                 495

Ser Trp Gly Leu Gly Cys Gly Gln Lys Asp Val Pro Gly Val Tyr Thr
            500                 505                 510

Lys Val Thr Asn Tyr Leu Asp Trp Ile Arg Asp Asn Met Arg Pro
        515                 520                 525
```

2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 527 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```
Ser Tyr Gln Val Ile Cys Arg Asp Glu Lys Thr Gln Met Ile Tyr Gln
1               5                  10                  15

Gln His Gln Ser Trp Leu Arg Pro Val Leu Arg Ser Asn Arg Val Glu
            20                  25                  30

Tyr Cys Trp Cys Asn Ser Gly Arg Ala Gln Cys His Ser Val Pro Val
        35                  40                  45

Lys Ser Cys Ser Glu Pro Arg Cys Phe Asn Gly Gly Thr Cys Gln Gln
    50                  55                  60

Ala Leu Tyr Phe Ser Asp Phe Val Cys Gln Cys Pro Glu Gly Phe Ala
65                  70                  75                  80

Gly Lys Cys Cys Glu Ile Asp Thr Arg Ala Thr Cys Tyr Glu Asp Gln
                85                  90                  95

Gly Ile Ser Tyr Arg Gly Thr Trp Ser Thr Ala Glu Ser Gly Ala Glu
            100                 105                 110

Cys Thr Asn Trp Asn Ser Ser Ala Leu Ala Gln Lys Pro Tyr Ser Gly
        115                 120                 125

Arg Arg Pro Asp Ala Ile Arg Leu Gly Leu Gly Asn His Asn Tyr Cys
    130                 135                 140

Arg Asn Pro Asp Arg Asp Ser Lys Pro Trp Cys Tyr Val Phe Lys Ala
145                 150                 155                 160

Gly Lys Tyr Ser Ser Glu Phe Cys Ser Thr Pro Ala Cys Ser Glu Gly
                165                 170                 175

Asn Ser Asp Cys Tyr Phe Gly Asn Gly Ser Ala Tyr Arg Gly Thr His
            180                 185                 190

Ser Leu Thr Glu Ser Gly Ala Ser Cys Leu Pro Trp Asn Ser Met Ile
        195                 200                 205

Leu Ile Gly Lys Val Tyr Thr Ala Gln Asn Pro Ser Ala Gln Ala Leu
    210                 215                 220

Gly Leu Gly Lys His Asn Tyr Cys Arg Asn Pro Asp Gly Asp Ala Lys
225                 230                 235                 240

Pro Trp Cys His Val Leu Lys Asn Arg Arg Leu Thr Trp Glu Tyr Cys
                245                 250                 255

Asp Val Pro Ser Cys Ser Thr Cys Gly Leu Arg Gln Tyr Ser Gln Pro
            260                 265                 270
```

Gln Phe Glu Ile Lys Gly Gly Leu Phe Ala Asp Ile Ala Ser His Pro
275 280 285

Trp Gln Ala Ala Ile Phe Ala Lys His Arg Arg Ser Pro Gly Glu Arg
290 295 300

Phe Leu Cys Gly Gly Ile Leu Ile Ser Ser Cys Trp Ile Leu Ser Ala
305 310 315 320

Ala His Cys Phe Gln Glu Arg Phe Pro Pro His His Leu Thr Val Ile
325 330 335

Leu Gly Arg Thr Tyr Arg Val Val Pro Gly Glu Glu Glu Gln Lys Phe
340 345 350

Glu Val Glu Lys Tyr Ile Val His Lys Glu Phe Asp Asp Asp Thr Tyr
355 360 365

Asp Asn Asp Ile Ala Leu Leu Gln Leu Lys Ser Asp Ser Ser Arg Cys
370 375 380

Ala Gln Glu Ser Ser Val Val Arg Thr Val Cys Leu Pro Pro Ala Asp
385 390 395 400

Leu Gln Leu Pro Asp Trp Thr Glu Cys Glu Leu Ser Gly Tyr Gly Lys
405 410 415

His Glu Ala Leu Ser Pro Phe Tyr Ser Glu Arg Leu Tyr Glu Ala His
420 425 430

Val Arg Leu Tyr Pro Ser Ser Arg Cys Thr Ser Gln His Leu Leu Asn
435 440 445

Arg Thr Val Thr Asp Asn Met Leu Cys Ala Gly Asp Thr Arg Ser Gly
450 455 460

Gly Pro Gln Ala Asn Leu His Asp Ala Cys Gln Gly Asp Ser Gly Gly
465 470 475 480

Pro Leu Val Cys Leu Asn Asp Gly Arg Met Thr Leu Val Gly Ile Ile
485 490 495

Ser Trp Gly Leu Gly Cys Gly Gln Lys Asp Val Pro Gly Val Tyr Thr
500 505 510

Lys Val Thr Asn Tyr Leu Asp Trp Ile Arg Asp Asn Met Arg Pro
515 520 525

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 290 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CTACGGCAAG CATGAGGCCT TGTCTCCTTT CTATTCGGAG CGGCTGAAGG AGGCTCATGT 60

CAGACTGTAC CCATCCAGCC GCTGCACATC ACAACATTTA CTTAACAGAA CAGTCACCGA 120

CAACATGCTG TGTGCTGGAG ACACTCGGAG CGGCGGGCCC CAGGCAAACT TGCACGACGC 180

CTGCCAGGGC GATTCGGGAG GCCCCCTGGT GTGTCTGAAC GATGGCCGCA TGACTTTGGT 240

GGGCATCATC AGCTGGGGCC TGGGCTGTGG ACAGAAGGAT GTCCCGGGTG 290

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 290 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CTACGGCAAG GACGAGGCCT TGTCTCCTTT CTATTCGGAG CGGCTGAAGG AGGCTCATGT 60

CAGACTGTAC CCATCCAGCC GCTGCACATC ACAACATTTA CTTAACAGAA CAGTCACCGA 120

CAACATGCTG TGTGCTGGAG ACACTCGGAG CGGCGGGCCC CAGGCAAACT TGCACGACGC 180

CTGCCAGGGC GATTCGGGAG GCCCCCTGGT GTGTCTGAAC GATGGCCGCA TGACTTTGGT 240

GGGCATCATC AGCTGGGGCC TGGGCTGTGG ACAGAAGGAT GTCCCGGGTG 290

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 290 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CTACGGCAAG GAGGAGGCCT TGTCTCCTTT CTATTCGGAG CGGCTGAAGG AGGCTCATGT 60

CAGACTGTAC CCATCCAGCC GCTGCACATC ACAACATTTA CTTAACAGAA CAGTCACCGA 120

CAACATGCTG TGTGCTGGAG ACACTCGGAG CGGCGGGCCC CAGGCAAACT TGCACGACGC 180

CTGCCAGGGC GATTCGGGAG GCCCCCTGGT GTGTCTGAAC GATGGCCGCA TGACTTTGGT 240

GGGCATCATC AGCTGGGGCC TGGGCTGTGG ACAGAAGGAT GTCCCGGGTG 290

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 290 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CTACGGCAAG CATGAGGCCT TGTCTCCTTT CTATTCGGAG CGGCTGTATG AGGCTCATGT 60

CAGACTGTAC CCATCCAGCC GCTGCACATC ACAACATTTA CTTAACAGAA CAGTCACCGA 120

CAACATGCTG TGTGCTGGAG ACACTCGGAG CGGCGGGCCC CAGGCAAACT TGCACGACGC 180

CTGCCAGGGC GATTCGGGAG GCCCCCTGGT GTGTCTGAAC GATGGCCGCA TGACTTTGGT 240

GGGCATCATC AGCTGGGGCC TGGGCTGTGG ACAGAAGGAT GTCCCGGGTG 290

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CTACGGCAAG GACGAGGCCT TGT 23

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CTACGGCAAG GAGGAGGCCT TGT 23

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CGGAGCGGCT GTATGAGGCT MCATGT 25

I claim:

1. A variant single chain human tissue-type plasminogen activator protein having R275 and at least one other basic amino acid residue in the serine protease region substituted by a non-basic amino acid residue thereby disrupting the salt bridge interaction between aspartate 477 and lysine 429.

2. The protein of claim 1 wherein the non-basic amino acid residue is chosen from the group consisting of glycine, serine, threonine, asparagine, tyrosine, glutamine, aspartic acid, and glutamic acid and having a zymogenicity of at least 10.

3. The protein of claim 1 having a zymogenicity of at least 50.

4. The protein of claim 1 having a zymogenicity of at least 100.

5. The protein of claim 1 having a fibrin stimulation factor of at least 10,000.

6. The protein of claim 1 having a fibrin stimulation factor of at least 20,000.

7. The protein of claim 1 having a fibrin stimulation factor of at least 10,000.

8. The protein of claim 2 having a fibrin stimulation factor of at least 20,000.

9. The protein of claim 3 having a fibrin stimulation factor of at least 20,000.

10. The protein of claim 1 wherein the protein is at least a factor of 5 less inhibited by PAI-1 compared to wild type single chain human tissue-type plasminogen activator protein.

11. The protein of claim 1 wherein the protein is at least a factor of 9 less inhibited by PAI-1 compared to wild type single chain human tissue-type plasminogen activator protein.

12. The protein of claim 1 wherein the protein is at least a factor of 200 less inhibited by PAI-1 compared to wild type single chain human tissue-type plasminogen activator protein.

13. The protein of claim 8 wherein the protein is at least a factor of 9 less inhibited by PAI-1 compared to wild type single chain human tissue-type plasminogen activator protein.

14. The protein of claim 8 wherein the protein is at least a factor of 200 less inhibited by PAI-1 compared to wild type single chain human tissue-type plasminogen activator protein.

15. The protein of claim 1 wherein the protein has a fibrin selectivity factor of at least 100.

16. The protein of claim 8 wherein the protein has a fibrin selectivity factor of at least 100.

17. The protein of claim 14 wherein the protein has a fibrin selectivity factor of at least 100.

18. A polynucleotide encoding the protein of claim 1.

19. An expression vector comprising the polynucleotide of claim 18.

20. A cell comprising the expression vector of claim 19.

21. A variant single chain human tissue-type plasminogen activator protein selected from the group consisting of R275E,H417D, R275E,H417E and R275E,K429Y.

22. A polynucleotide encoding the protein of claim 21.

23. An expression vector comprising the polynucleotide of claim 22.

24. A cell comprising the expression vector of claim 23.

25. A composition for the treatment of an thrombotic condition comprising a physiologically effective amount of the protein of claim 1 in a pharmaceutically suitable excipient.

26. The composition of claim 25 wherein the dose of the protein is from about 0.05 milligram per kilogram body weight to about 0.2 milligrams per kilogram body weight.

27. A diagnostic kit comprising antibodies to the protein of claim 1.

28. A diagnostic kit comprising the protein of claim 1.

29. A diagnostic kit comprising polynucleotides capable of hybridizing to the polynucleotide of claim 18.

30. A method of making a variant single chain human tissue-type plasminogen activator protein comprising the steps of culturing the cell of claim 24.

31. The method of claim 30 further comprising the additional step of purifying the protein.

```
GTTCTGAGCACAGGGCTGGAGAGAAAACCTCTGCGAGGAAAGGGAAGGAGCAAGCCGTGA

                                  -35                   -30
                                  met asp ala met lys arg gly leu
ATTTAAGGGACGCTGTGAAGCAATC         ATG GAT GCA ATG AAG AGA GGG CTC

                                  -20
cys cys val leu leu leu cys gly ala val phe val ser pro ser
TGC TGT GTG CTG CTG CTG TGT GGA GCA GTC TTC GTT TCG CCC AGC

         -10                                              1
gln glu ile his ala arg phe arg arg gly ala arg SER TYR GLN
CAG GAA ATC CAT GCC CGA TTC AGA AGA GGA GCC AGA TCT TAC CAA

                                 10
VAL ILE CYS ARG ASP GLU LYS THR GLN MET ILE TYR GLN GLN HIS
GTG ATC TGC AGA GAT GAA AAA ACG CAG ATG ATA TAC CAG CAA CAT

     20                                              30
GLN SER TRP LEU ARG PRO VAL LEU ARG SER ASN ARG VAL GLU TYR
CAG TCA TGG CTG CGC CCT GTG CTC AGA AGC AAC CGG GTG GAA TAT

                                 40
CYS TRP CYS ASN SER GLY ARG ALA GLN CYS HIS SER VAL PRO VAL
TGC TGG TGC AAC AGT GGC AGG GCA CAG TGC CAC TCA GTG CCT GTC

     50                                              60
LYS SER CYS SER GLU PRO ARG CYS PHE ASN GLY GLY THR CYS GLN.
AAA AGT TGC AGC GAG CCA AGG TGT TTC AAC GGG GGC ACC TGC CAG

                                 70
GLN ALA LEU TYR PHE SER ASP PHE VAL CYS GLN CYS PRO GLU GLY
CAG GCC CTG TAC TTC TCA GAT TTC GTG TGC CAG TGC CCC GAA GGA

     80                                              90
PHE ALA GLY LYS CYS CYS GLU ILE ASP THR ARG ALA THR CYS TYR
TTT GCT GGG AAG TGC TGT GAA ATA GAT ACC AGG GCC ACG TGC TAC

                                100
GLU ASP GLN GLY ILE SER TYR ARG GLY THR TRP SER THR ALA GLU
GAG GAC CAG GGC ATC AGC TAC AGG GGC ACG TGG AGC ACA GCG GAG

    110                                             120
SER GLY ALA GLU CYS THR ASN TRP ASN SER SER ALA LEU ALA GLN
AGT GGC GCC GAG TGC ACC AAC TGG AAC AGC AGC GCG TTG GCC CAG

                                130
LYS PRO TYR SER GLY ARG ARG PRO ASP ALA ILE ARG LEU GLY LEU
AAG CCC TAC AGC GGG CGG AGG CCA GAC GCC ATC AGG CTG GGC CTG

    140                                             150
GLY ASN HIS ASN TYR CYS ARG ASN PRO ASP ARG ASP SER LYS PRO
GGG AAC CAC AAC TAC TGC AGA AAC CCA GAT CGA GAC TCA AAG CCC
```

FIG. 1A

```
                                    160
TRP CYS TYR VAL PHE LYS ALA GLY LYS TYR SER SER GLU PHE CYS
TGG TGC TAC GTC TTT AAG GCG GGG AAG TAC AGC TCA GAG TTC TGC

    170                                                 180
SER THR PRO ALA CYS SER GLU GLY ASN SER ASP CYS TYR PHE GLY
AGC ACC CCT GCC TGC TCT GAG GGA AAC AGT GAC TGC TAC TTT GGG

                                    190
ASN GLY SER ALA TYR ARG GLY THR HIS SER LEU THR GLU SER GLY
AAT GGG TCA GCC TAC CGT GGC ACG CAC AGC CTC ACC GAG TCG GGT

    200                                                 210
ALA SER CYS LEU PRO TRP ASN SER MET ILE LEU ILE GLY LYS VAL
GCC TCC TGC CTC CCG TGG AAT TCC ATG ATC CTG ATA GGC AAG GTT

                                    220
TYR THR ALA GLN ASN PRO SER ALA GLN ALA LEU GLY LEU GLY LYS
TAC ACA GCA CAG AAC CCC AGT GCC CAG GCA CTG GGC CTG GGC AAA

    230                                                 240
HIS ASN TYR CYS ARG ASN PRO ASP GLY ASP ALA LYS PRO TRP CYS
CAT AAT TAC TGC CGG AAT CCT GAT GGG GAT GCC AAG CCC TGG TGC

                                    250
HIS VAL LEU LYS ASN ARG ARG LEU THR TRP GLU TYR CYS ASP VAL
CAC GTG CTG AAG AAC CGC AGG CTG ACG TGG GAG TAC TGT GAT GTG

    260                                                 270
PRO SER CYS SER THR CYS GLY LEU ARG GLN TYR SER GLN PRO GLN
CCC TCC TGC TCC ACC TGC GGC CTG AGA CAG TAC AGC CAG CCT CAG

                                    280
PHE ARG ILE LYS GLY GLY LEU PHE ALA ASP ILE ALA SER HIS PRO
TTT CGC ATC AAA GGA GGG CTC TTC GCC GAC ATC GCC TCC CAC CCC

    290                                                 300
TRP GLN ALA ALA ILE PHE ALA LYS HIS ARG ARG SER PRO GLY GLU
TGG CAG GCT GCC ATC TTT GCC AAG CAC AGG AGG TCG CCC GGA GAG

                                    310
ARG PHE LEU CYS GLY GLY ILE LEU ILE SER SER CYS TRP ILE LEU
CGG TTC CTG TGC GGG GGC ATA CTC ATC AGC TCC TGC TGG ATT CTC

    320                                                 330
SER ALA ALA HIS CYS PHE GLN GLU ARG PHE PRO PRO HIS HIS LEU
TCT GCC GCC CAC TGC TTC CAG GAG AGG TTT CCG CCC CAC CAC CTG

                                    340
THR VAL ILE LEU GLY ARG THR TYR ARG VAL VAL PRO GLY GLU GLU
ACG GTG ATC TTG GGC AGA ACA TAC CGG GTG GTC CCT GGC GAG GAG
```

FIG. 1B

```
    350                                                 360
GLU GLN LYS PHE GLU VAL GLU LYS TYR ILE VAL HIS LYS GLU PHE
GAG CAG AAA TTT GAA GTC GAA AAA TAC ATT GTC CAT AAG GAA TTC

                        370
ASP ASP ASP THR TYR ASP ASN ASP ILE ALA LEU LEU GLN LEU LYS
GAT GAT GAC ACT TAC GAC AAT GAC ATT GCG CTG CTG CAG CTG AAA

    380                                                 390
SER ASP SER SER ARG CYS ALA GLN GLU SER SER VAL VAL ARG THR
TCG GAT TCG TCC CGC TGT GCC CAG GAG AGC AGC GTG GTC CGC ACT

                        400
VAL CYS LEU PRO PRO ALA ASP LEU GLN LEU PRO ASP TRP THR GLU
GTG TGC CTT CCC CCG GCG GAC CTG CAG CTG CCG GAC TGG ACG GAG

    410                                                 420
CYS GLU LEU SER GLY TYR GLY LYS HIS GLU ALA LEU SER PRO PHE
TGT GAG CTC TCC GGC TAC GGC AAG CAT GAG GCC TTG TCT CCT TTC

                        430
TYR SER GLU ARG LEU LYS GLU ALA HIS VAL ARG LEU TYR PRO SER
TAT TCG GAG CGG CTG AAG GAG GCT CAT GTC AGA CTG TAC CCA TCC

    440                                                 450
SER ARG CYS THR SER GLN HIS LEU LEU ASN ARG THR VAL THR ASP
AGC CGC TGC ACA TCA CAA CAT TTA CTT AAC AGA ACA GTC ACC GAC

                        460
ASN MET LEU CYS ALA GLY ASP THR ARG SER GLY GLY PRO GLN ALA
AAC ATG CTG TGT GCT GGA GAC ACT CGG AGC GGC GGG CCC CAG GCA

    470                                                 480
ASN LEU HIS ASP ALA CYS GLN GLY ASP SER GLY GLY PRO LEU VAL
AAC TTG CAC GAC GCC TGC CAG GGC GAT TCG GGA GGC CCC CTG GTG

                        490
CYS LEU ASN ASP GLY ARG MET THR LEU VAL GLY ILE ILE SER TRP
TGT CTG AAC GAT GGC CGC ATG ACT TTG GTG GGC ATC ATC AGC TGG

    500                                                 510
GLY LEU GLY CYS GLY GLN LYS ASP VAL PRO GLY VAL TYR THR LYS
GGC CTG GGC TGT GGA CAG AAG GAT GTC CCG GGT GTG TAC ACC AAG

                        520                             527
VAL THR ASN TYR LEU ASP TRP ILE ARG ASP ASN MET ARG PRO OP
GTT ACC AAC TAC CTA GAC TGG ATT CGT GAC AAC ATG CGA CCG TGA
```

FIG. 1C

CCAGGAACACCCGACTCCTCAAAAGCAAATGAGATCCCGCCTCTTCTTCTTCAGAAGACA
CTGCAAAGGCGCAGTGCTTCTCTACAGACTTCTCCAGACCCACCACACCGCAGAAGCGGG
ACGAGACCCTACAGGAGAGGGAAGAGTGCATTTTCCCAGATACTTCCCATTTTGGAAGT
TTTCAGGACTTGGTCTGATTTCAGGATACTCTGTCAGATGGGAAGACATGAATGCACACT
AGCCTCTCCAGGAATGCCTCCTCCCTGGGCAGAAAGTGGCCATGCCACCCTGTTTTCAGCTA
AAGCCCAACCTCCTGACCTGTCACCGTGAGCAGCTTTGGAAACAGGACCACAAAAATGAA
AGCATGTCTCAATAGTAAAAGATAACAAGATCTTTCAGGAAAGACGGATTGCATTAGAA
ATAGACAGTATATTTATAGTCACAAGAGCCCAGCAGGGCCTCAAAGTTGGGGCAGGCTGGC
TGGCCCGTCATGTTCCTCAAAAGCACCCTTGACGTCAAGTCTCCTTCCCCTTTCCCCACT
CCCTGGCTCTCAGAAGGTATTCCTTTTGTGTACAGTGTGTAAAGTGTAAATCCTTTTTCT
TTATAAACTTTAGAGTAGCATGAGAGAATTGTATCATTTGAACAACTAGGCTTCAGCATA
TTTATAGCAATCCATGTTAGTTTTTACTTTCTGTTGCCACAACCCTGTTTTATACTGTA
CTTAATAAATTCAGATATATTTTTCACAGTTTTTCCAAAAAAAAAAAAA

FIG. 1D

FIG. 2A



FIG. 2B



FIG. 2C



FIG. 2D



INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/20226

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N9/72 //C12N15/55

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PETERSEN L C ET AL: "QUENCHING OF THE AMIDOLYTIC ACTIVITY OF ONE-CHAIN TISSUE-TYPE PLASMINOGEN ACTIVATOR BY MUTATION OF LYSINE-416" BIOCHEMISTRY, vol. 29, no. 14, 1990, WASHINGTON US, pages 3451-3457, XP002053064	1-4, 18-20, 25,26,29
Y	see the whole document, especially page 3452, column 2, last paragraph - page 3453, column 3, first paragraph and page 3456, column 1, last paragraph	21-24

-/--

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publicationdate of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of theinternational search	Date of mailing of the international search report
8 May 1998	22/05/1998

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	De Kok, A

Form PCT/ISA/210 (second sheet) (July 1992)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
X	TACHIAS K ET AL: "Variants of tissue-type plasminogen activator which display substantially enhanced stimulation by fibrin" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 31, 4 August 1995, BALTIMORE US, pages 18319-18322, XP002063362 see the whole document	1,2,5-9, 15-17
Y	WO 90 02798 A (GENENTECH INC) 22 March 1990 cited in the application see page 2, line 28 - page 5, line 38 see page 10, line 19 - line 40 see page 11, line 31 - line 35 see page 19, line 22 - page 20, line 25 see page 31, line 11 - page 32, line 13 see page 33, line 14 - line 35	21-24
A		1-9, 15-20, 25,26, 30,31
A	EP 0 199 574 A (GENENTECH INC) 29 October 1986 cited in the application see page 3, line 4 - page 8, line 8 see page 10, line 4 - line 26 see page 24, line 25 - page 30, line 4	1-4, 18-31

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 97/20226

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9002798 A	22-03-90	US 5108901 A	28-04-92
		AT 124452 T	15-07-95
		AU 626323 B	30-07-92
		AU 4194689 A	02-04-90
		DE 68923298 D	03-08-95
		DK 36991 A	02-05-91
		EP 0457758 A	27-11-91
		HU 213922 B	28-11-97
		IE 67508 B	03-04-96
		IL 91306 A	14-08-97
		IL 109735 A	20-11-97
		IL 111767 A	15-04-97
		JP 4500157 T	16-01-92
		US 5520913 A	28-05-96
		US 5405771 A	11-04-95
		US 5411871 A	02-05-95
		US 5616486 A	01-04-97
		US 5614190 A	25-03-97
		US 5156969 A	20-10-92
		US 5728567 A	17-03-98
		US 5714145 A	03-02-98
		US 5258180 A	02-11-93
		US 5262170 A	16-11-93
EP 0199574 A	29-10-86	AU 596356 B	03-05-90
		AU 5641686 A	30-10-86
		DE 3613390 A	30-10-86
		DE 3682104 A	28-11-91
		DE 3689386 D	27-01-94
		DE 3689386 T	19-05-94
		DK 181286 A	23-10-86
		DK 181386 A	23-10-86
		EP 0200451 A	05-11-86
		FI 861673 A,B,	23-10-86
		FR 2581652 A	14-11-86
		GB 2173804 A,B	22-10-86
		IE 62206 B	28-12-94
		IE 58574 B	06-10-93
		JP 2529816 B	04-09-96
		JP 6277071 A	04-10-94

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter. onal Application No
PCT/US 97/20226

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0199574 A		JP 7040940 B	10-05-95
		JP 62000024 A	06-01-87
		NO 175216 B	06-06-94
		PT 82429 B	03-03-88
		US 5736134 A	07-04-98
		US 5714372 A	03-02-98
		US 5073494 A	17-12-91
		US 5147643 A	15-09-92
		US 5219569 A	15-06-93

19

PATENT COOPERATION TREATY

PCT

REC'D 04 MAR 1999
WIPO PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
97,707		
International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/US97/20226	12/11/1997	12/11/1996
International Patent Classification (IPC) or national classification and IPC C12N9/72		
Applicant THE SCRIPPS RESEARCH INSTITUTE et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 9 sheets, including this cover sheet.

   ☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of 4 sheets.

3. This report contains indications relating to the following items:

   - I ☒ Basis of the report
   - II ☒ Priority
   - III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
   - IV ☐ Lack of unity of invention
   - V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations suporting such statement
   - VI ☐ Certain documents cited
   - VII ☐ Certain defects in the international application
   - VIII ☐ Certain observations on the international application

Date of submission of the demand	Date of completion of this report
10/06/1998	
Name and mailing address of the international preliminary examining authority: European Patent Office D-80298 Munich Tel. (+49-89) 2399-0 Tx: 523656 epmu d Fax: (+49-89) 2399-4465	Authorized officer van Heusden, M Telephone No. (+49-89) 2399 8145

Form PCT/IPEA/409 (cover sheet) (January 1994)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US97/20226

I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

Description, pages:

1-4,6-11,13-27	as originally filed	
5,12	with telefax of	14/01/1999

Claims, No.:

1-16	with telefax of	14/01/1999
17-32	with telefax of	28/01/1999

Drawings, sheets:

1/5-5/5	as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

see separate sheet

II. Priority

1. ☐ This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:

   ☐ copy of the earlier application whose priority has been claimed.

☐ translation of the earlier application whose priority has been claimed.

2. ☐ This report has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid.

Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:

see separate sheet

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 27, 29.

because:

☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):

☒ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. 27, 29 are so unclear that no meaningful opinion could be formed (*specify*):

see separate sheet

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☐ no international search report has been established for the said claims Nos. .

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	2-17, 21-26, 28, 30-32
	No:	Claims	1, 18-20
Inventive step (IS)	Yes:	Claims	3-17, 32
	No:	Claims	1-2, 18-26, 28, 30-31
Industrial applicability (IA)	Yes:	Claims	1-26, 28, 30-32
	No:	Claims	

2. Citations and explanations

see separate sheet

Additional remarks to section I:

The amendment to claim 3 (replacement of 'zymogenicity of at least **50**' for 'at least **75**') does not have a basis in the application as originally filed. Although the applicant indicates p. 7, line 2 as the basis for the amendment, this passage discloses a zymogenicity of at least 10, preferably of a range of about 50 to about 200. Therefore the specific value of **75** is not disclosed and the amendment introduces a random selection of the range as originally disclosed. The amendment fulfills the requirements of Article 19(2) and Rule 70.2(c) **only** if the applicant can show a basis for the specific value of **75** in the application as originally filed.

Additional remarks to section II:

The priority document pertaining to the present application was not available at the time of establishing this IPER. Hence, the current assessment is based on the assumption that all claims enjoy priority rights from the filing date of the priority document.

Additional remarks to section III:

Claims 27 and 29 cannot be examined because of lack of clarity. Claim 27 refers to a diagnostic kit comprising antibodies to the t-PA variant of the present invention, and lacks clarity in that it does not provide any technical specification of said antibodies. Therefore it is impossible to compare the subject matter of this claim with the prior art. Moreover, antibodies against the t-PA variant of the present invention could be reactive against any part of the protein, including any epitope outside the region of the substituted amino acids. Therefore the antibodies could react with wild-type t-PA, which could result in a lack of novelty.

Similarly, claim 29 refers to polynucleotides capable of hybridizing to the polynucleotide encoding the t-PA variant of the present invention. This claim also lacks clarity in that it does not provide any technical specification of said

polynucleotides. Therefore, also for this claim it is impossible to compare the subject matter to the prior art. In addition, a polynucleotide as defined in claim 29 could hybridize with any part of the t-PA variant polynucleotide, also outside the region of the substituted amino acids, and thus also with wild-type tPA polynucleotides, which could result in an objection for lack of novelty. Even if the polynucleotides would be complementary to the region containing the substituted amino acids, depending on the length of the polynucleotides and the hybridization conditions, said polynucleotides could still be hybridizing to wild-type t-PA.

Additional remarks to section V:

1. Citations

The documents mentioned in this IPER are numbered as in the International Search Report (ISR), i.e. D1 corresponds to the first document of the ISR etc.

The following document is cited from examiner's own knowledge:

D5: EP-A-0351246

A copy of this document is annexed to the communication.

2. Novelty (Article 33(2) PCT)

2.1 The present application discloses a variant single chain human tissue-type plasminogen activator (t-PA) protein having R275 and at least one other basic amino acid residue in the serine protease region substituted by a non-basic amino acid residue. It further discloses a polynucleotide encoding said t-PA, an expression vector comprising said polynucleotide and a cell comprising said vector. It further relates to a composition comprising said t-PA variant for treatment of a thrombotic condition, as well as diagnostic kits.

2.2 The present application does not satisfy the criterion set forth in Article 33(2) PCT because the subject matter of claims 1 and 18-20 is not novel in respect of

document D1.

2.3 Document D1 discloses a t-PA variant having a R275L substitution and at least one other basic amino acid residue in the serine protease region substituted by a non-basic amino acid residue (K277L, see abstract). The subject matter of claim 1 includes the additional functional feature 'thereby disrupting the salt bridge interaction between aspartate 477 and lysine 429'. This feature is not a measurable parameter and is therefore meaningless for the definition of the scope of the claim. Indeed, the specification does not report any test that could be used to asses this functional feature. In addition, this feature is entirely hypothetical as indicated by the applicant himself (p. 18, l. 16; p. 19, l. 17; p. 25, l. 15 and p. 27 l. 13 and 16). Therefore this feature has not been taken into account when assessing novelty of claim 1.

D1 also describes the DNA encoding the variant, an expression vector containing said DNA and a cell comprising said expression vector (p. 3452, left column, l. 7-right column, l. 6). Therefore D1 anticipates the subject matter of claims 1 and 18-20.

3. Inventive step (Article 33(3) PCT)

3.1 The present application does not satisfy the criterion set forth in Article 33(3) PCT because the subject matter of claims 2, 21-26, 28 and 30-31 does not involve an inventive step.

3.2 The closest prior art to asses the inventiveness of the subject matter of claim 2 is document D1, which discloses a t-PA variant in which R275 is substituted for glycine and a second t-PA variant in which one other basic amino acid residue in the serine protease region (K416) is substituted for serine (see abstract). This second K416S-t-PA variant has a zymogenicity of 57 (p. 3454, Table II). The subject matter of claim 2 differs from the teachings in D1 only in that the two substitutions are combined in one t-PA variant. Document D2 teaches the combination of a substitution at the proteolytic cleavage site (the R275E substitution) with an additional substitution in the serine protease region of t-PA that decreases proteolytic activity of the single chain zymogen and thus increases

zymogenicity. It would be obvious for the skilled person to combine the teachings of these two documents, to arrive at the t-PA variant as defined in claim 2.

3.3 The closest prior art to evaluate the inventiveness of the subject matter of claim 21 is document D2. D2 discloses a t-PA variant comprising the R275E substitution in combination with a second substitution F305H that increases zymogenicity (see abstract and Figure 1). The subject matter of claim 21 differs from the teachings in D2 only in that the R275E substitution is combined with a different second substitution. Therefore the problem to be solved by the present invention may be regarded as finding a further second substitution that increases zymogenicity. D1 indicates that H417 may be involved in the putative salt-bridge interaction that is responsible for the enzyme activity of the zymogen (p. 3453, left column, l. 21-24). Both D1 (Fig. 2 and Table II) and D5 (Fig. 6A) show that a combination substitution of K416S,H417T results in decreased proteolytic activity of the single chain zymogen and thus in increased zymogenicity. No inventive skill is required to choose the H417 amino acid from these two substitutions, and to substitute it with further non-basic amino acids, to arrive at the R275E,H417D or the R275E,H417E t-PA variant of the present invention.

Moreover, no surprising effect is obtained with the R275E,H417(D/E) t-PA variants since their zymogenicity (17 and 13, respectively, p. 16, Table 1) is much lower than that of the K416S t-PA variant of D1 (57, p. 3454, Table II).

D5 further discloses a DNA encoding the variant (claims 15-18), in an expression vector (claim 19), in a host cell (claim 20), and a composition for treatment of a thrombotic condition, comprising the t-PA variant (p. 5, l. 59 - p. 6, l. 2). It also discloses a method for making the t-PA variant recombinantly (claims 24 and 25). Therefore also claims 22-26, 28 and 30-31 are objected to for lack of inventive step.

3.4 The applicant is already informed that, in the case that the above objection to claim 21 for lack of inventive step can be overcome, an objection for lack of unity will be raised. The general concept linking together the three embodiments of claim 21 appears to be either claim 1, which is not novel as argued above under 2.3, or claim 2, which is not inventive as argued above under 3.2.

3.5 The third embodiment of the present application is the R275E,K429Y t-PA variant. Document D3 discloses a combination substitution of E426,R427,K429,E430 which results in decreased proteolytic activity of the single chain zymogen and thus in increased zymogenicity (Tables I and II). However, D3 does not indicate which of these four substitutions is responsible for the observed changes in enzyme activity. In addition, D1 indicates that K429 is not likely to be involved in the putative salt-bridge formation. Therefore it would not be obvious for the skilled person to test the K429Y substitution. Thus an inventive step can be recognized for the R275E,K429Y t-PA variant as claimed in claim 32. Claims 22-26, 28 and 30-31 would fulfill the requirements of inventive step only in so far as they refer to said inventive t-PA variant.

4. Industrial applicability (Article 33(4) PCT)

Claims 1-26, 28 and 30-32 are considered to have industrial applicability.

I claim:

1. A variant single chain human tissue-type plasminogen activator protein having R275 and at least one other basic amino acid residue in the serine protease region substituted by a non-basic amino acid residue thereby disrupting the salt bridge interaction between aspartate 477 and lysine 429.

2. The protein of claim 1 wherein the non-basic amino acid residue is chosen from the group consisting of glycine, serine, threonine, asparagine, tyrosine, glutamine, aspartic acid, and glutamic acid and having a zymogenicity of at least 10.

3. The protein of claim 1 having a zymogenicity of at least 50.

4. The protein of claim 1 having a zymogenicity of at least 100.

5. The protein of claim 1 having a fibrin stimulation factor of at least 10,000.

6. The protein of claim 1 having a fibrin stimulation factor of at least 20,000.

7. The protein of claim 1 having a fibrin stimulation factor of at least 10,000.

8. The protein of claim 2 having a fibrin stimulation factor of at least 20,000.

9. The protein of claim 3 having a fibrin stimulation factor of at least 20,000.

10. The protein of claim 1 wherein the protein is at least a factor of 5 less inhibited by PAI-1 compared to wild type single chain human tissue-type plasminogen activator protein.

11. The protein of claim 1 wherein the protein is at least a factor of 9 less inhibited by PAI-1 compared to wild type single chain human tissue-type plasminogen activator protein.

12. The protein of claim 1 wherein the protein is at least a factor of 200 less inhibited by PAI-1 compared to wild type single chain human tissue-type plasminogen activator protein.

13. The protein of claim 8 wherein the protein is at least a factor of 9 less inhibited by PAI-1 compared to wild type single chain human tissue-type plasminogen activator protein.

14. The protein of claim 8 wherein the protein is at least a factor of 200 less inhibited by PAI-1 compared to wild type single chain human tissue-type plasminogen activator protein.

15. The protein of claim 1 wherein the protein has a fibrin selectivity factor of at least 100.

16. The protein of claim 8 wherein the protein has a fibrin selectivity factor of at least 100.

17. The protein of claim 14 wherein the protein has a fibrin selectivity factor of at least 100.

18. A polynucleotide encoding the protein of claim 1.

19. An expression vector comprising the polynucleotide of claim 18.

20. A cell comprising the expression vector of claim 19.

21. A variant single chain human tissue-type plasminogen activator protein selected from the group consisting of R275E,H417D, R275E,H417E and R275E,K429Y.

22. A polynucleotide encoding the protein of claim 21.

23. An expression vector comprising the polynucleotide of claim 22.

24. A cell comprising the expression vector of claim 23.

25. A composition for the treatment of an thrombotic condition comprising a physiologically effective amount of the protein of claim 1 in a pharmaceutically suitable excipient.

26. The composition of claim 25 wherein the dose of the protein is from about 0.05 milligram per kilogram body weight to about 0.2 milligrams per kilogram body weight.

27. A diagnostic kit comprising antibodies to the protein of claim 1.

28. A diagnostic kit comprising the protein of claim 1.

29. A diagnostic kit comprising polynucleotides capable of hybridizing to the polynucleotide of claim 18.

30. A method of making a variant single chain human tissue-type plasminogen activator protein comprising the steps of culturing the cell of claim 24.

31. The method of claim 30 further comprising the additional step of purifying the protein.

therapeutic compositions thus include the cDNA compounds themselves as naked DNA, presented as part of a viral vector delivery system or other vector-based gene expression delivery system, presented in a liposome delivery system and the like.

The recombinant expressed t-PA variant proteins of the present invention are contemplated as thrombolytic therapeutic agents for ameliorating the same conditions outlined above. Based on the individual structural and functional properties of various t-PA variant proteins described above, the selection of the particular t-PA variant is determined by the desired therapeutic outcome. For example, the fibrinogen-mediated activation of endogenous human t-PA is activated by bleeding which then results in a widespread undesired systemic response. Thus, to mediate fibrinolytic processes locally in either an acute or chronic thrombotic condition while simultaneously preventing proteolytic activation systemically, one would therefore use the t-PA variant, namely R275E,K429Y, that is primarily activated by fibrin and not fibrinogen. A composition for use as thrombolytic therapeutic agents generally a physiologically effective amount of the t-PA variant protein in a pharmaceutically suitable excipient. Depending on the mode of administration and the condition to be treated, the thrombolytic therapeutic agents are administered in single or multiple doses. If "bolus" doses are administered, doses of about 0.01 to about 0.6 mg/kg will typically be administered, preferably doses of about 0.05 to about 0.2 mg/kg, with subsequent administrations of about 0.1 to about 0.2 mg/kg to maintain a t-PA blood level of about 3 microgram/ml. One skilled in the art will appreciate that variations in dosage depend on the condition to be treated. In other applications, a composition of variant t-PA in a gel composition is useful in preventing the formation of adhesions.

Other variations and uses of the present invention will be apparent to one skilled in the art.

Example 1

Site Directed Mutagenesis And Construction Of Expression Vectors Encoding Variants Of T-PA

Oligonucleotide directed site specific mutagenesis was performed by the method of Zoller and Smith (Zoller, M. I., and Smith, M. (1984) DNA 3, 479-488) as modified by Kunkel (Kunkel, T. A. (1985) Proc. Natl. Acad. Sci. U.S.A. 82, 488-492). Mutations were introduced into the 290 bp *Sac*I – *Sma*I fragment of cDNA encoding t-PA that had been

del-51–173), PCT 87/04722 (deletion of all or part of the N-terminal 1 - 91), EPO Publ. No. 231,624 (all of growth factor domain deleted), and EPO Publ. No. 242,836 and Jap. Pat. Appl. Kokai No. 62 - 269688 (some or all of the growth factor domain deleted).

It has further been shown that t-PA can be modified both in the region of the first kringle domain and in the growth factor domain, resulting in increased circulatory half-life. See EPO Pat. Publ. No. 241,208 published Oct. 14, 1987. The region between amino acids 51 and 87, inclusive, can be deleted from t-PA to result in a variant having slower clearance from plasma. Browne et al., *J. Biol. Chem.*, **263:** 1599–1602 (1988). Also, t-PA can be modified, without adverse biological effects, in the region of amino acids 67 to 69 of the mature, native t-PA, by deletion of certain amino acid residues or replacement of one or more amino acids with different amino acids. See EPO Pat. Publ. No. 240,334 published Oct. 7, 1987.

A hybrid of t-PA/urokinase using the region of t-PA encompassing amino acids 273 - 527 is also disclosed. See EPO 290,118 published Nov. 9, 1988. Serpin-resistant mutants of human t-PA with alterations in the protease domain, including del296-302 t-PA, R304S t-PA, and R304E t-PA, are disclosed in Madison et al., *Nature*, **339:** 721–724 (1989). The above list is not an exhaustive review of the numerous variants of t-PA that have described.

As a result of the catalytic activity of precursor t-PA, despite effective clot lysis at targeted sites, nondesirable proteolysis occurs systemically resulting in the deleterious depletion of circulating fibrinogen, α2-anti-plasmin and plasminogen. What is needed are more zymogenic t-PA variant proteins that provide effective local clot lysis is achieved with diminished systemic proteolytic effects.

Summary of the Invention

The present invention provides single chain variant t-PA proteins having at least two substitutions of basic amino acid residues by neutral or acidic amino acid residues, compared to the wild-type human t-PA, as well as polynucleotides encoding such single chain variant t-PA proteins. The single chain variant t-PA proteins of the present invention have the R275 amino acid residue substituted by an amino acid residue chosen from the group consisting of glycine, serine, threonine, asparagine, tyrosine, glutamine, aspartic acid, and glutamic acid. Preferably the single chain variant t-PA proteins of the present invention have the R275 amino